<% provide(:title, 'Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii
                            ') %>
<% provide(:description, '') %>

<section class="pb-5">
    <div class="container">
        <div class="row">
            <div class="col-xl-8 col-lg-10 mx-auto">
                <div class="text-content text-lg">
                    <main class="c-content-layout__main">
                        <article itemscope="" itemtype="http://schema.org/ScholarlyArticle">


                            <div class="FulltextWrapper">
                                <ul class="c-article-identifiers u-reset-list">
                                    <li class="c-article-identifiers__item" data-test="article-category">Research</li>
                                    <li class="c-article-identifiers__item" data-test="open-access">
                                        <span class="u-text-open-access">Open Access</span>
                                    </li>


                                </ul>
                            </div>

                            <div class="FulltextWrapper"><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="MainTitleSection"><h1 xmlns="http://www.w3.org/1999/xhtml" class="ArticleTitle" itemprop="headline" lang="en">Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8<sup xmlns:func="http://oscar.fig.bmc.com">+</sup>T cell epitope based, adjuvanted vaccine protective against <em xmlns="" class="EmphasisTypeItalic">Toxoplasma gondii</em>
                            </h1></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AuthorNames" data-author-affiliations="true"><ul class="u-listReset"><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Hua&nbsp;Cong</span><sup><a href="#Aff1_50" class="AffiliationID">1_50</a>, <a href="#Aff2_50" class="AffiliationID">2_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Ernest&nbsp;J&nbsp;Mui</span><sup><a href="#Aff1_50" class="AffiliationID">1_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">William&nbsp;H&nbsp;Witola</span><sup><a href="#Aff1_50" class="AffiliationID">1_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">John&nbsp;Sidney</span><sup><a href="#Aff3_50" class="AffiliationID">3_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Jeff&nbsp;Alexander</span><sup><a href="#Aff4_50" class="AffiliationID">4_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Alessandro&nbsp;Sette</span><sup><a href="#Aff3_50" class="AffiliationID">3_50</a></sup>, </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Ajesh&nbsp;Maewal</span><sup><a href="#Aff5_50" class="AffiliationID">5_50</a></sup> and </li><li class="Author hasAffil" data-jumpto="Aff" data-test="author-name"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName" itemprop="author" itemscope="" itemtype="http://schema.org/Person">Rima&nbsp;McLeod</span><sup><a href="#Aff6_50" class="AffiliationID">6_50</a></sup><a href="mailto:rmcleod@midway.uchicago.edu" class="EmailAuthor" title="Email author"><span class="ContactIcon" aria-hidden="true"></span><span class="u-srOnly">Email author</span></a></li></ul></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="ArticleContextInformation"><div class="ContextInformation"><div class="ContextInformationJournalTitles"><span class="ArticleCitation"><span itemscope="" itemtype="http://schema.org/Periodical" itemid="#periodical"><span xmlns="http://www.w3.org/1999/xhtml" class="JournalTitle">Immunome Research</span></span><span class="ArticleCitation_Year">2010</span><span class="ArticleCitation_Volume"><strong itemprop="isPartOf" itemtype="http://schema.org/PublicationVolume"><link itemprop="isPartOf" href="#periodical">6</strong>:12</span></span></div><p class="ArticleDOI"><a itemprop="sameAs" class="u-text-inherit" href="https://doi.org/10.1186/1745-7580-6-12">https://doi.org/10.1186/1745-7580-6-12</a></p><p class="Copyright">© &nbsp;Cong et al.&nbsp;2010</p></div></div><ul class="ArticleHistory u-reset-list"><li class="History HistoryReceived"><strong>Received: </strong><span>28&nbsp;September&nbsp;2010</span></li><li class="History HistoryAccepted"><strong>Accepted: </strong><span>3&nbsp;December&nbsp;2010</span></li><li class="History HistoryOnlineDate"><strong>Published: </strong><span itemprop="datePublished">3&nbsp;December&nbsp;2010</span></li></ul></div>





                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Abstract Section1 RenderAsSection1 c-section" id="Abs1_50" lang="en"><h2 class="c-section__heading"><a href="#Abstract" data-test="abstract-heading" data-disable-click-event-default="">Abstract</a></h2><div class="c-section__content" id="Abstract"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec1_50">
                                <h3 xmlns="" class="Heading">Background</h3>
                                <p class="Para">Toxoplasmosis causes loss of life, cognitive and motor function, and sight. A vaccine is greatly needed to prevent this disease. The purpose of this study was to use an immmunosense approach to develop a foundation for development of vaccines to protect humans with the HLA-A03 supertype. Three peptides had been identified with high binding scores for HLA-A03 supertypes using bioinformatic algorhythms, high measured binding affinity for HLA-A03 supertype molecules, and ability to elicit IFN-γ production by human HLA-A03 supertype peripheral blood CD8<sup>+</sup> T cells from seropositive but not seronegative persons.</p>
                            </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec2_50">
                                <h3 xmlns="" class="Heading">Results</h3>
                                <p class="Para">Herein, when these peptides were administered with the universal CD4<sup>+</sup>T cell epitope PADRE (AKFVAAWTLKAAA) and formulated as lipopeptides, or administered with GLA-SE either alone, or with Pam<sub>2</sub>Cys added, we found we successfully created preparations that induced IFN-γ and reduced parasite burden in HLA-A*1101(an HLA-A03 supertype allele) transgenic mice. GLA-SE is a novel emulsified synthetic TLR4 ligand that is known to facilitate development of T Helper 1 cell (TH1) responses. Then, so our peptides would include those expressed in tachyzoites, bradyzoites and sporozoites from both Type I and II parasites, we used our approaches which had identified the initial peptides. We identified additional peptides using bioinformatics, binding affinity assays, and study of responses of HLA-A03 human cells. Lastly, we found that immunization of HLA-A*1101 transgenic mice with all the pooled peptides administered with PADRE, GLA-SE, and Pam<sub>2</sub>Cys is an effective way to elicit IFN-γ producing CD8<sup>+</sup> splenic T cells and protection. Immunizations included the following peptides together: KSFKDILPK (SAG1<sub>224-232</sub>); AMLTAFFLR (GRA6<sub>164-172</sub>); RSFKDLLKK (GRA7<sub>134-142</sub>); STFWPCLLR (SAG2C<sub>13-21</sub>); SSAYVFSVK(<sub>SPA250-258</sub>); and AVVSLLRLLK(SPA<sub>89-98</sub>). This immunization elicited robust protection, measured as reduced parasite burden using a luciferase transfected parasite, luciferin, this novel, HLA transgenic mouse model, and imaging with a Xenogen camera.</p>
                            </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec3_50">
                                <h3 xmlns="" class="Heading">Conclusions</h3>
                                <p class="Para"><em xmlns="" class="EmphasisTypeItalic">Toxoplasma gondii</em> peptides elicit HLA-A03 restricted, IFN-γ producing, CD8<sup>+</sup> T cells in humans and mice. These peptides administered with adjuvants reduce parasite burden in HLA-A*1101 transgenic mice. This work provides a foundation for immunosense based vaccines. It also defines novel adjuvants for newly identified peptides for vaccines to prevent toxoplasmosis in those with HLA-A03 supertype alleles.</p>
                            </div></div></section><section xmlns:func="http://oscar.fig.bmc.com" class="KeywordGroup Section1 RenderAsSection1 c-section" lang="en"><h2 xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Keywords" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Keywords">Keywords</a></h2><div class="js-CollapseSection CollapseSection c-section__content" data-test="collapse-section" id="Keywords"><ul class="c-keywords"><li class="c-keywords__item" itemprop="about">Cell Epitope</li><li class="c-keywords__item" itemprop="about">Lipopeptide</li><li class="c-keywords__item" itemprop="about">Immunize Mouse</li><li class="c-keywords__item" itemprop="about">ELISpot Assay</li><li class="c-keywords__item" itemprop="about">Peptide Pool</li></ul></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec1_50" class="Section1 RenderAsSection1 c-section"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Background" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Background">Background</a></h2><div class="js-CollapseSection CollapseSection c-section__content" id="Background" data-test="collapse-section"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Toxoplasmosis is a disease of major medical importance. <em xmlns="" class="EmphasisTypeItalic">Toxoplasma gondii</em> causes congenital infections responsible for stillbirths and spontaneous abortions[<span class="CitationRef"><a href="#CR1_50" data-toggle="citation">1</a></span><span>, <span class="CitationRef"><a href="#CR2" data-toggle="citation">2</a></span>, <span class="CitationRef"><a href="#CR3" data-toggle="citation">3</a></span>, <span class="CitationRef"><a href="#CR4" data-toggle="citation">4</a></span>, </span><span class="CitationRef"><a href="#CR5_50" data-toggle="citation">5</a></span>]. In addition, it causes neurologic disorders, uveitis, and systemic infections in immune-compromised patients. <em xmlns="" class="EmphasisTypeItalic">Toxoplasmic</em> encephalitis is a cause of morbidity and mortality in those with congenital disease and persons with AIDS[<span class="CitationRef"><a href="#CR6_50" data-toggle="citation">6</a></span>]. <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> is acquired by consumption of lightly cooked meat, especially lamb and pork contaminated with bradyzoites[<span class="CitationRef"><a href="#CR7_50" data-toggle="citation">7</a></span>, <span class="CitationRef"><a href="#CR8_50" data-toggle="citation">8</a></span>] or by ingestion of food or water contaminated with oocysts containing sporozoites, which are the product of a sexual cycle in the intestine of the cat [<span class="CitationRef"><a href="#CR8_50" data-toggle="citation">8</a></span>, <span class="CitationRef"><a href="#CR9_50" data-toggle="citation">9</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Development of an effective vaccine would prevent this disease. Attenuated <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> tachyzoites (e.g., S48, TS-4, T-203, ΔRPS13)have been employed for live vaccinations of non-human animals[<span class="CitationRef"><a href="#CR10_50" data-toggle="citation">10</a></span><span>, <span class="CitationRef"><a href="#CR11" data-toggle="citation">11</a></span>, <span class="CitationRef"><a href="#CR12" data-toggle="citation">12</a></span>, <span class="CitationRef"><a href="#CR13" data-toggle="citation">13</a></span>, <span class="CitationRef"><a href="#CR14" data-toggle="citation">14</a></span>, </span><span class="CitationRef"><a href="#CR15_50" data-toggle="citation">15</a></span>]. Parasites attenuated by knockout of gene transcription recently have been proposed as a new type of attenuated vaccine candidate[<span class="CitationRef"><a href="#CR13_50" data-toggle="citation">13</a></span><span>, <span class="CitationRef"><a href="#CR14" data-toggle="citation">14</a></span>, </span><span class="CitationRef"><a href="#CR15_50" data-toggle="citation">15</a></span>]. However, safety considerations may limit vaccination of humans with live organisms. Development of peptide-based vaccines created with epitopes which elicit IFN-γ production by CD8<sup>+</sup> T cells[<span class="CitationRef"><a href="#CR16_50" data-toggle="citation">16</a></span>] is a promising strategy to mobilize the immune system against <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> in humans[<span class="CitationRef"><a href="#CR16_50" data-toggle="citation">16</a></span><span>, <span class="CitationRef"><a href="#CR17" data-toggle="citation">17</a></span>, <span class="CitationRef"><a href="#CR18" data-toggle="citation">18</a></span>, <span class="CitationRef"><a href="#CR19" data-toggle="citation">19</a></span>, </span><span class="CitationRef"><a href="#CR20_50" data-toggle="citation">20</a></span>]. Thus, an effort to create an immunosense epitope-based vaccine was initiated.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Recently, three peptide epitopes, KSFKDILPK (SAG1<sub>224-232</sub>), AMLTAFFLR (GRA6<sub>164-172</sub>), and RSFKDLLKK (GRA7<sub>134-142</sub>), were found by our group to elicit IFN-γ from peripheral blood mononuclear leukocytes (PBMCs) from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> seropositive HLA-A03 supertype humans but not from PBMCs of <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> seronegative HLA-A03 supertype humans[<span class="CitationRef"><a href="#CR18_50" data-toggle="citation">18</a></span>]. Herein, initially we designed 4 CD8<sup>+</sup> T cell epitope containing vaccine formulations comprised of lipopeptides that incorporate PADRE as well as a novel oil-in-water emulsion that includes a specially formulated synthetic MLA derivative called GLA-SE[<span class="CitationRef"><a href="#CR21_50" data-toggle="citation">21</a></span><span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation">22</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation">23</a></span>, </span><span class="CitationRef"><a href="#CR24_50" data-toggle="citation">24</a></span>]. First, efficacy of various vaccine formulations consisting of the three previously identified CD8<sup>+</sup> T cell peptides eliciting HLA-A*1101-restricted, CD8<sup>+</sup>T cell-mediated IFN-γ production <em xmlns="" class="EmphasisTypeItalic">in vitro</em> from HLA-A*1101 mice was examined.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Then, in order to identify additional peptides from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> tachyzoites, bradyzoites and sporozoites of Type I and Type II strains that are effective in eliciting IFN-γ from HLA-A03 supertype restricted CD8<sup>+</sup> T cells, the first step was to select proteins with biologic properties, such as being secreted, compatible with MHC Class I processing. Then, bioinformatic algorithms to identify HLA-A03 supertype bound peptides were utilized to find additional, novel <em xmlns="" class="EmphasisTypeItalic">T. gondii</em>-derived, potential CD8<sup>+</sup> T cell eliciting epitopes restricted by the HLA-A03 supertype. We screened peptides from tachyzoite, bradyzoite and sporozoite proteins (GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, MIC) of the type II <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> strain, ME49, searching for those with high binding scores in a bioinformatic analysis (IC<sub>50</sub> &lt; 50 nM) and then in binding assays. In addition, peripheral blood mononuclear cells from seropositive and seronegative persons were tested for response to these peptides using an IFN-γ ELISpot assay. These latter studies were performed to attempt to identify other peptides that would be promising candidates for inclusion in a multi-epitope, next generation immunosense vaccine. Then, information obtained from testing the first three peptides studied was used to guide formulation and administration of a peptide pool. This pool included the first three peptides identified earlier and tested in the initial experiments combined with the newly identified peptides that elicited IFN-γ from human HLA-A03 supertype restricted CD8<sup>+</sup> T cells. All the peptides in this pool were tested with a universal T helper epitope called PADRE and a new, promising adjuvant called GLA-SE with Pam<sub>2</sub>Cys in HLA-A*1101 transgenic mice. Capacity to induce IFN-γ production by spleen CD8<sup>+</sup> T cells, and to protect against parasite burden following subsequent challenge were determined. For parasite challenge, a luciferase transfected Type II Prugneaud parasite was administered, followed by luciferin administration and imaging with a Xenogen camera system a week later. This allows detection and quantization of bioluminescent parasites as a biomarker to assess efficacy of immunizations in protection.</p></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec2_50" class="Section1 RenderAsSection1 c-section"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Results" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Results">Results</a></h2><div class="js-CollapseSection CollapseSection c-section__content" id="Results" data-test="collapse-section"><section id="Sec3_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Construction of CD4-CD8 lipopeptide based candidate vaccine</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Three CD8<sup>+</sup> T cell epitopes had been identified from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> proteins, based on their significant recognition by T cells from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> seropositive HLA-A03 individuals[<span class="CitationRef"><a href="#CR18_50" data-toggle="citation">18</a></span>]. A universal CD4<sup>+</sup> T cell epitope, PADRE (AKFVAAWTLKAAA), was linked in sequence with the N-terminal end of each of the three different <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> CD8<sup>+</sup> T cell epitopes: KSFKDILPK (SAG1<sub>224-232</sub>), AMLTAFFLR (GRA6<sub>164-172</sub>), RSFKDLLKK (GRA7<sub>134-142</sub>). Also, these three epitopes were linked together with three alanines as the linker. The N-terminal end of each resulting CD4-CD8 peptide or polypeptide was extended by a lysine covalently linked to two molecules of the palmitic acid moiety. The lipopeptides (Lp) were named as LpKS9, LpAM9, LpRS9 and LpKS9-AM9-RS9. They are shown in Figure <span class="InternalRef"><a href="#Fig1_50">1</a></span>.<figure xmlns="" class="Figure" id="Fig1_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig1_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig1_HTML.jpg" alt="Figure 1" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig1_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig1_HTML.jpg" alt="Figure 1"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 1</span>
                                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Schematic representation of the synthetic lipopeptide immunogens used in this study</strong>. The C-terminal end of a promiscuous CD4<sup xmlns="http://www.w3.org/1999/xhtml">+</sup> T cell peptide epitope (PADRE) was joined in sequence with the N-terminal end of one of three different <em class="EmphasisTypeItalic">T. gondii</em> CD8 T cell epitopes: SAG1<sub xmlns="http://www.w3.org/1999/xhtml">224-232</sub> (A), GRA6<sub xmlns="http://www.w3.org/1999/xhtml">164-172</sub> (B); GRA7<sub xmlns="http://www.w3.org/1999/xhtml">134-142</sub> (C) or three epitopes linked together (D) with a three alanine linker. The N-terminal end of each resulting CD4-CD8 peptide was extended by a lysine covalently linked to one molecule of palmitic acid. This results in a four lipopeptides construct.</p>
                                        <p xmlns="" class="SimplePara">The abbreviation Lp is used throughout the manuscript whenever the lipopeptide (Lp) has been studied. When there is a mixture of components or undivided components they are named individually. Sequence of PADRE is AKFVAAWTLKAAA. Structure of Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys is PAM<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>KSS. a = abbreviation for name of protein from which peptide is derived.</p>
                                    </div></figcaption></figure>
                                    </div>
                                </section><section id="Sec4_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Immunogenicity of lipopeptides in HLA-A*1101 transgenic mice</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">HLA-A*1101 transgenic mice were immunized twice at intervals of three weeks with lipopeptides which were administered in PBS. Two weeks after the last immunization, the spleens were removed from immunized mice and the ability of splenocytes to produce IFN-γ upon stimulation with peptides was analyzed. Transgenic mice immunized with the three single peptide lipopeptide vaccines had T cells that produced IFN-γ (Figure <span class="InternalRef"><a href="#Fig2_50">2</a></span>). The lipopeptide vaccines LpKS9 and LpAM9 stimulated higher IFN-γ production than LpRS9 (Figure <span class="InternalRef"><a href="#Fig2_50">2</a></span>). However, LpKS9-AM9-RS9 with three peptide epitopes linked together did not stimulate strong IFN-γ responses when splenocytes from these mice were exposed to each of the individual peptides <em xmlns="" class="EmphasisTypeItalic">in vitro</em>. Only results with LpKS9(KS9) and LpAM9(AM9) achieved statistical significance (Figure <span class="InternalRef"><a href="#Fig2_50">2</a></span>).<figure xmlns="" class="Figure" id="Fig2_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig2_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig2_HTML.jpg" alt="Figure 2" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig2_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig2_HTML.jpg" alt="Figure 2"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 2</span>
                                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">HLA-A*1101 mice immunized with lipopeptides</strong>. Mice were immunized with lipopeptides: LpKS9, LpAM9, LpRS9 and LpKS9-AM9-RS9 which were shown in Figure 1. The mice were immunized twice at intervals of three weeks. Ten to fourteen days after the last immunization, spleen cells were separated from immunized mice and stimulated by appropriate peptides in an <em class="EmphasisTypeItalic">ex vivo</em> IFN-γ ELISpot assay. Data presented are averages of three independent replicate experiments. *, <em class="EmphasisTypeItalic">P</em> &lt; 0.05; **, <em class="EmphasisTypeItalic">P</em> &lt; 0.01.</p>
                                    </div></figcaption></figure>
                                    </div>
                                </section><section id="Sec5_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Comparison of vaccination with different formulations of peptides</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In order to determine which formulation was most immunogenic, vaccination with a single peptide or a mixture of the peptides was compared with linked lipopeptide vaccines. Results of a representative experiment are presented in Figure <span class="InternalRef"><a href="#Fig3_50">3</a></span>. Mice immunized with a vaccine formulated with a single peptide SAG1<sub>224-232</sub>, KS9-PADRE with the adjuvancy of GLA-SE and Pam<sub>2</sub>Cys, elicited IFN-γ production (SFC:248 ± 65; mean ± SEM) four-fold higher (p &lt; 0.01) than mice that received LpKS9 GLA-SE vaccination (63 ± 17)(Figure <span class="InternalRef"><a href="#Fig3_50">3a</a></span>). Similar results, with substantial IFN-γ production, were found when splenocytes from mice immunized with a mixture of peptides and adjuvants. These results were compared with IFN-γ production by splenocytes from mice immunized with a lipopeptide vaccine constructed with the three peptides linked together with alanine spacers LpKS9-AM9-RS9. Significant IFN-γ production was only present with KS9 and AM9 stimulation of spleen cells, and was much less robust and not significant when the spleen cells were stimulated by RS9 peptide.<figure xmlns="" class="Figure" id="Fig3_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig3_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig3_HTML.jpg" alt="Figure 3" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig3_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig3_HTML.jpg" alt="Figure 3"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 3</span>
                                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Lipopeptides vaccine compared with peptide pool vaccine</strong>. HLA-A*1101 transgenic mice were immunized either with lipopeptides or a mixture of peptides plus GLA-SE and Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys. LpKS9 and KS9/PADRE/GLA-SE/Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys (Figure 3a), LpKS9-AM9-RS9 and KS9/AM9/RS9/PADRE/GLA-SE/Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys (Figure 3b) were used as immunogens. For the lipopeptide immunizations, the mice were vaccinated twice at intervals of three weeks. For the immunizations containing individual components including the same peptides, the mice were vaccinated three times at intervals of two weeks. Ten to fourteen days after the last immunization, spleen cells were separated from immunized mice and stimulated by the appropriate peptide in an <em class="EmphasisTypeItalic">ex vivo</em> IFN-γ ELISpot assay. Data presented are a representative example from three independent experiments. *, <em class="EmphasisTypeItalic">P</em> &lt; 0.05; **, <em class="EmphasisTypeItalic">P</em> &lt; 0.01.</p>
                                    </div></figcaption></figure>
                                    </div>
                                </section><section id="Sec6_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Effects of adjuvant on immunogenicity of pooled peptide vaccination</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">To determine whether, and if so how, adjuvants effected immunogenicity of these peptides, HLA-A*1101 transgenic mice were immunized with pools of peptides that included all of the three peptides (KS9, AM9, RS9) alone or with varying adjuvants. HLA-A*1101 transgenic mice were immunized with: (1) CD8<sup>+</sup> epitope peptide pool, (2) peptide pool plus PADRE, (3) peptide pool plus PADRE emulsified with GLA-SE, and (4) peptide pool plus PADRE and Pam<sub>2</sub>Cys emulsified with GLA-SE. Mice were inoculated three times at intervals of two weeks. Eleven to fourteen days post immunization, spleen cells were isolated and exposed to each individual peptide. A peptide was considered immunogenic if it induced IFN-γ spot formation that was significantly higher in the immunization group compared with the group inoculated with PBS. After the immunizations, only KS9 and AM9 were found to be immunogenic in HLA-A*1101 transgenic mice, and only when the iniversal CD4<sup>+</sup> helper T cell peptide epitope PADRE was included. Robust responses were observed when GLA-SE was added in the vaccine. Greater responses were elicited when Pam<sub>2</sub>Cys was used as an adjuvant for some peptides but did not enhance responses to all of them, and in fact reduced the effect of some peptides. Figure <span class="InternalRef"><a href="#Fig4_50">4</a></span> shows the representative data of IFN-γ spot formation from the four immunization groups which were stimulated by individual peptides.<figure xmlns="" class="Figure" id="Fig4_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig4_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig4_HTML.jpg" alt="Figure 4" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig4_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig4_HTML.jpg" alt="Figure 4"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 4</span>
                                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">HLA-A*1101 transgenic mice immunized with peptide pool and adjuvants</strong>. Mice were immunized with PBS, peptide pool, peptide pool with PADRE, peptide pool with PADRE in GLA-SE, peptide pool with PADRE and Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys in GLA-SE. Splenic T cells were isolated 10-14 days post-immunization and exposed to each peptide in an <em class="EmphasisTypeItalic">ex vivo</em> IFN-γ ELISpot assay.</p>
                                    </div></figcaption></figure>
                                    </div>
                                </section><section id="Sec7_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Vaccination with peptide pools and adjuvants protects mice against type II parasite challenge</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">HLA-A*1101 transgenic mice were immunized with peptide pools plus PADRE and Pam<sub>2</sub>Cys in GLA-SE three times at intervals of two weeks. Mice were challenged 2 weeks after the last immunization. They were imaged 7 days after they had been challenged with 10,000 Pru (Fluc) using the Xenogen <em xmlns="" class="EmphasisTypeItalic">in vivo</em> imaging system. As shown in Figure <span class="InternalRef"><a href="#Fig5_50">5</a></span>, numbers of luciferase expressing parasites in immunized HLA-A*1101 transgenic mice were significantly less compared to numbers of parasites in unimmunized mice. Mean [standard deviation](median) was 136[253](30) million for nonimmunized mice versus 5[<span class="CitationRef"><a href="#CR4_50" data-toggle="citation">4</a></span>](5) million for immunized mice. With natural log transformed data, means[standard deviations] were 3.6[<span class="CitationRef"><a href="#CR1_50" data-toggle="citation">1</a></span>, <span class="CitationRef"><a href="#CR6_50" data-toggle="citation">6</a></span>] for nonimmunized mice versus 1.4[.8] for immunized mice. Differences were significant (e.g., p &lt; 0.0064, for the pooled experiments, using natural log transformed data and two-sample t test).<figure xmlns="" class="Figure" id="Fig5_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig5_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig5_HTML.jpg" alt="Figure 5" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig5_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig5_HTML.jpg" alt="Figure 5"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 5</span>
                                        <p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">In vivo</span><strong class="EmphasisTypeBold">protection demonstrated with imaging using Xenogen camera</strong>. HLA-A*1101 transgenic mice immunized with peptide pool and adjuvants were protected compared to control mice inoculated with PBS when they were challenged with 10,000 Prugneaud strain (Fluc)-<em class="EmphasisTypeItalic">T. gondii</em> luciferase expressing parasites. There were a total of 5-9(usually 4-5 per group) mice tested in each control or immunization group. Differences between control and immunization groups were significant(p &lt; 0.0064 using natural log transformed data and two-sample t test).</p>
                                    </div></figcaption></figure>
                                    </div>
                                </section><section id="Sec8_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Identification of new candidate <em class="EmphasisTypeItalic">T. gondii</em> specific HLA-A*1101-restricted epitopes</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We initially identified 3 epitopes that provided protection against parasite challenge. As a next generation vaccine that might be even more robust, elicit CD8<sup>+</sup>T cells that would be effective against all three life cycle stages and Type I and II genetic types of the parasite, we sought to identify additional HLA-A11 epitopes to be used for vaccine development. In order to identify additional peptides from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> that were present in tachyzoites, bradyzoites, and sporozoites of Type II strains for HLA-A03 supertype restricted CD8<sup>+</sup> T cells, we screened candidate peptides from tachyzoite, bradyzoite and sporozoite proteins (GRA15, GRA10, SAG2C, SAG2X, SAG3, SRS9, SPA and MIC) of the Type II <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> strain (Tables <span class="InternalRef"><a href="#Tab1_50">1</a></span> and <span class="InternalRef"><a href="#Tab2_50">2</a></span>). For parsimony in numbers of peptides utilized, we attempted to include peptides present in Type I as well as Type II parasite genetic types. Peripheral blood mononuclear cells from seropositive <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> donors were tested for response to these peptides by using the IFN-γ ELISpot assay. Pooled peptides were tested initially. Pools 2 and 5 were significantly different (p &lt; 0.05) from the control (data not shown). Then the individual peptides were tested (Figure <span class="InternalRef"><a href="#Fig6_50">6</a></span>). Three out of 34 epitopes elicited responses greater than 50 IFN-γ SFC from seropositive donors PBMC, but not from seronegative donors PBMC (Figure <span class="InternalRef"><a href="#Fig6_50">6</a></span>). These peptides and the proteins from which they are derived are: STFWPCLLR (SAG2C<sub>13-21</sub>); SSAYVFSVK (SPA<sub>250-258</sub>); and AVVSLLRLLK (SPA<sub>89-98</sub>) adding proteins expressed in sporozoites and bradyzoites to the peptides selected. All peptides identified herein then were found to show high binding affinity to three to five HLA-A03 supertype alleles in the MHC-peptide binding assay (Table <span class="InternalRef"><a href="#Tab3_50">3</a></span>). The numbers in Table <span class="InternalRef"><a href="#Tab3_50">3</a></span> which indicate high binding affinity are those less than 500 IC<sub>50</sub> nM. They are indicated by bolded font numbers in Table <span class="InternalRef"><a href="#Tab3_50">3</a></span>.<figure xmlns="" id="Tab1_50" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 1</span>
                                        <p xmlns="" class="SimplePara">Peptides, their affinity for HLA-A*1101, and their immunogenicity in humans and for transgenic mice</p>
                                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col><col><col><col><col><col></colgroup><thead><tr class="header"><th><p xmlns="" class="SimplePara">Peptide Sequences</p></th><th><p xmlns="" class="SimplePara">Protein<sup xmlns="http://www.w3.org/1999/xhtml">1</sup>
                                    </p></th><th><p xmlns="" class="SimplePara">Affinity<sup xmlns="http://www.w3.org/1999/xhtml">2</sup> HLA-A*1101</p></th><th colspan="2"><p xmlns="" class="SimplePara">Elicit IFN-γ<sup xmlns="http://www.w3.org/1999/xhtml">3</sup> in</p></th><th><p xmlns="" class="SimplePara">Immunogenicity<sup xmlns="http://www.w3.org/1999/xhtml">4</sup> in mice</p></th></tr><tr class="header"><th>&nbsp;</th><th>&nbsp;</th><th>&nbsp;</th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">Seropositive human</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">Seronegative human</strong>
                                    </p></th><th>&nbsp;</th></tr></thead><tbody><tr class="noclass"><td><p xmlns="" class="SimplePara">KSFKDILPK</p></td><td><p xmlns="" class="SimplePara">SAG1<sub xmlns="http://www.w3.org/1999/xhtml">224-232</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">54</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">+</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">AMLTAFFLR</p></td><td><p xmlns="" class="SimplePara">GRA6<sub xmlns="http://www.w3.org/1999/xhtml">164-172</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">3.6</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">+</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">RSFKDLLKK</p></td><td><p xmlns="" class="SimplePara">GRA7<sub xmlns="http://www.w3.org/1999/xhtml">134-142</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">14</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">-</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">STFWPCLLR</p></td><td><p xmlns="" class="SimplePara">SAG2C<sub xmlns="http://www.w3.org/1999/xhtml">13-21</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">+</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">SSAYVFSVK</p></td><td><p xmlns="" class="SimplePara">SPA<sub xmlns="http://www.w3.org/1999/xhtml">250-258</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">+</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">AVVSLLRLLK</p></td><td><p xmlns="" class="SimplePara">SPA<sub xmlns="http://www.w3.org/1999/xhtml">89-98</sub>
                                    </p></td><td><p xmlns="" class="SimplePara">34</p></td><td><p xmlns="" class="SimplePara">+</p></td><td><p xmlns="" class="SimplePara">-</p></td><td><p xmlns="" class="SimplePara">+</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">1</sup>Peptides derived from these proteins and the position within the proteins</p>
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">2</sup>Binding affinity was performed by MHC binding assay.</p>
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">3</sup>PBMC from four <em class="EmphasisTypeItalic">T. gondii</em>-seropositive HLA-A03 supertype persons and four seronegative persons were stimulated with peptides, the T cell that produce IFN-γ were tested by ELISpot assay.</p>
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">4</sup>Splenic T cell were isolated from HLA-A*03 supertype(which includes the HLA-A*1101 haplotype) mice 10 to 14 days after peptide immunization and tested for their ability to generate IFN-γ in response to peptide.</p>
                                    </div></figure>
                                        <figure xmlns="" id="Tab2_50" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 2</span>
                                            <p xmlns="" class="SimplePara">Predicted peptide candidates utilized for screening CD8+ T cells1</p>
                                        </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col><col><col><col><col><col><col></colgroup><thead><tr class="header"><th><p xmlns="" class="SimplePara">HLA-A*1101</p></th><th><p xmlns="" class="SimplePara">ANTIGEN</p></th><th><p xmlns="" class="SimplePara">PEPTIDE SEQUENCES</p></th><th><p xmlns="" class="SimplePara">LENGTH</p></th><th><p xmlns="" class="SimplePara">LOCATION</p></th><th><p xmlns="" class="SimplePara">PREDICTED IC<sub xmlns="http://www.w3.org/1999/xhtml">50</sub> nM</p></th><th><p xmlns="" class="SimplePara">POOL</p></th></tr></thead><tbody><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">GRA15</p></td><td><p xmlns="" class="SimplePara">STSPFATRK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">152-160</p></td><td><p xmlns="" class="SimplePara">5</p></td><td><p xmlns="" class="SimplePara">P1</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">GRA15</p></td><td><p xmlns="" class="SimplePara">ASTSPFATRK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">150-159</p></td><td><p xmlns="" class="SimplePara">18.2</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">GRA10</p></td><td><p xmlns="" class="SimplePara">AAAATPGLPK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">568-577</p></td><td><p xmlns="" class="SimplePara">9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">GRA10</p></td><td><p xmlns="" class="SimplePara">AAATPGLPK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">569-577</p></td><td><p xmlns="" class="SimplePara">13.2</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">GRA10</p></td><td><p xmlns="" class="SimplePara">GVPAVPGLLK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">507-516</p></td><td><p xmlns="" class="SimplePara">17</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">HLA-A*1101</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">GRA10</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">SVVEENTMAK</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">10</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">865-874</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">25.1</span>
                                        </p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">STFWPCLLR</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">13-21</p></td><td><p xmlns="" class="SimplePara">9.3</p></td><td><p xmlns="" class="SimplePara">P2</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">ALLDHVFIEK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">231-240</p></td><td><p xmlns="" class="SimplePara">11.9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">SSPQNIFYK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">290-298</p></td><td><p xmlns="" class="SimplePara">12.9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">STTGVGETGK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">163-172</p></td><td><p xmlns="" class="SimplePara">28.4</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">GTEYSLALK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">136-144</p></td><td><p xmlns="" class="SimplePara">35.4</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">HLA-A*1101</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">SAG2D</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">SSPQNIFYK</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">9</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">122-130</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">12.9</span>
                                        </p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2D</p></td><td><p xmlns="" class="SimplePara">ALLEHVFIEK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">63-72</p></td><td><p xmlns="" class="SimplePara">20.2</p></td><td><p xmlns="" class="SimplePara">P3</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2D</p></td><td><p xmlns="" class="SimplePara">SSAQTFFYK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">290-298</p></td><td><p xmlns="" class="SimplePara">1.8</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2D</p></td><td><p xmlns="" class="SimplePara">TVYFSCDPK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">154-162</p></td><td><p xmlns="" class="SimplePara">5.3</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG2D</p></td><td><p xmlns="" class="SimplePara">PSSAQTFFYK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">289-298</p></td><td><p xmlns="" class="SimplePara">17.9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SAG3</p></td><td><p xmlns="" class="SimplePara">VVGHVTLNK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">80-88</p></td><td><p xmlns="" class="SimplePara">15.4</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">HLA-A*1101</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">SAG3</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">KQYWYKIEK</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">9</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">145-153</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">19.3</span>
                                        </p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SRS9</p></td><td><p xmlns="" class="SimplePara">TTCSVLVTVK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">357-366</p></td><td><p xmlns="" class="SimplePara">20.6</p></td><td><p xmlns="" class="SimplePara">P4</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SRS9</p></td><td><p xmlns="" class="SimplePara">AAASVQVPLK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">140-149</p></td><td><p xmlns="" class="SimplePara">29.9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SRS9</p></td><td><p xmlns="" class="SimplePara">AIQSQKWTLK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">169-178</p></td><td><p xmlns="" class="SimplePara">35</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">BSR4</p></td><td><p xmlns="" class="SimplePara">TTRFVEIFPK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">284-293</p></td><td><p xmlns="" class="SimplePara">10.3</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">HLA-A*1101</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">BSR4</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">VSGSLTLSK</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">9</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">83-91</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">21.1</span>
                                        </p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">SSAYVFSVK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">250-258</p></td><td><p xmlns="" class="SimplePara">9.3</p></td><td><p xmlns="" class="SimplePara">P5</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">TSSAYVFSVK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">249-258</p></td><td><p xmlns="" class="SimplePara">12.2</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">YVFSVKELPK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">253-262</p></td><td><p xmlns="" class="SimplePara">18</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">KTEATYCYK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">262-270</p></td><td><p xmlns="" class="SimplePara">18.4</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">MTLMITRDSK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">195-204</p></td><td><p xmlns="" class="SimplePara">25.5</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">AVVSLLRLLK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">89-98</p></td><td><p xmlns="" class="SimplePara">6.5</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">HLA-A*1101</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">SPA</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">VVSLLRLLK</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">9</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">90-98</span>
                                        </p></td><td><p xmlns="" class="SimplePara">
                                            <span class="EmphasisTypeUnderline">7.2</span>
                                        </p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">MIC1</p></td><td><p xmlns="" class="SimplePara">LTLTFISTK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">338-346</p></td><td><p xmlns="" class="SimplePara">13.8</p></td><td><p xmlns="" class="SimplePara">P6</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">MIC3</p></td><td><p xmlns="" class="SimplePara">SVQLGSFDK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">32-40</p></td><td><p xmlns="" class="SimplePara">12.9</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">MIC4</p></td><td><p xmlns="" class="SimplePara">SAVWFGVAK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">16-24</p></td><td><p xmlns="" class="SimplePara">17.2</p></td><td>&nbsp;</td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">HLA-A*1101</p></td><td><p xmlns="" class="SimplePara">MICA2P</p></td><td><p xmlns="" class="SimplePara">GVMTPNQMVK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">63-72</p></td><td><p xmlns="" class="SimplePara">14.3</p></td><td>&nbsp;</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                                            <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">1</sup> Peptides derived from GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, MIC1, MICA2P were screened for potential supertype epitopes using the ARB algorithms from immunoepitope database at <span xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://www.iedb.org/" target="_blank" class="ext-link"><span class="RefSource">http://www.iedb.org/</span></a></span> on the basis of their predicted binding affinity to HLA-A*1101. A total of 34 unique peptides IC<sub xmlns="http://www.w3.org/1999/xhtml">50</sub> &lt; 50 nM (lower score, higher predicted binding affinity) of all ranked nonameric or decameric peptides were selected.</p>
                                        </div></figure>
                                        <figure xmlns="" class="Figure" id="Fig6_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                            <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig6_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig6_HTML.jpg" alt="Figure 6" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig6_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig6_HTML.jpg" alt="Figure 6"></img></a>
                                        </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 6</span>
                                            <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">New peptides tested with PBMCs from HLA-A03 seropositive and seronegative donors</strong>. Then Peripheral blood mononuclear cells from seropositive <em class="EmphasisTypeItalic">T. gondii</em> donors were tested for response to these predicted HLA-A03 supertype restricted CD8<sup xmlns="http://www.w3.org/1999/xhtml">+</sup> T cell epitope individual peptides by using IFN-γ ELISpot assay. Peptides that induced significant IFN-γ spot formation compared to DMSO are denoted by an asterisk. *, <em class="EmphasisTypeItalic">P</em> &lt; 0.05.</p>
                                        </div></figcaption></figure>
                                    </div>
                                    <figure id="Tab3_50" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 3</span>
                                        <p xmlns="" class="SimplePara">MHC binding affinity assay for peptides that were identified with predictive algorithms for HLA-A03 supertype</p>
                                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col><col><col><col><col><col><col><col><col><col><col></colgroup><thead><tr class="header"><th>&nbsp;</th><th>&nbsp;</th><th>&nbsp;</th><th>&nbsp;</th><th colspan="6"><p xmlns="" class="SimplePara">HLA-A03-SUPERTYPE</p></th><th>&nbsp;</th></tr><tr class="header"><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">PEPTIDE SEQUENCE</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">LENGTH</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">PROTEIN</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">POSITION</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*0301</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*1101</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*3001</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*3101</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*3301</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">HLA-A*6801</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">SUPERTYPE ALLELES BOUND</strong>
                                    </p></th></tr></thead><tbody><tr class="noclass"><td><p xmlns="" class="SimplePara">STFWPCLLR</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">SAG2C</p></td><td><p xmlns="" class="SimplePara">13-21</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">22</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">10</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">1272</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">1.2</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">3.4</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">0.97</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">SSAYVFSVK</p></td><td><p xmlns="" class="SimplePara">9</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">250-258</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">12</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">10</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">1826</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">97</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">181</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">2.1</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">AVVSLLRLLK</p></td><td><p xmlns="" class="SimplePara">10</p></td><td><p xmlns="" class="SimplePara">SPA</p></td><td><p xmlns="" class="SimplePara">89-98</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">17</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">34</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">8.1</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">1296</p></td><td><p xmlns="" class="SimplePara">1100</p></td><td><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">94</strong>
                                    </p></td><td><p xmlns="" class="SimplePara">4</p></td></tr></tbody></table></div></figure>
                                </section><section id="Sec9_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Vaccination with peptide pools including newly identified peptides and adjuvants elicits IFN-γ and provides more protection to mice against Type II parasite challenge</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Then, HLA-A*1101 transgenic mice were immunized with peptide pools which included these newly identified peptides: KSFKDILPK (SAG1<sub>224-232</sub>); AMLTAFFLR (GRA6<sub>164-172</sub>); RSFKDLLKK (GRA7<sub>134-142</sub>); STFWPCLLR (SAG2C<sub>13-21</sub>); SSAYVFSVK (SPA<sub>250-258</sub>); AVVSLLRLLK (SPA<sub>89-98</sub>) plus PADRE and Pam<sub>2</sub>Cys in GLA-SE, They were immunized three times at intervals of two weeks. Significant IFN-γ spot formation responses were observed <em xmlns="" class="EmphasisTypeItalic">in vitro</em> by the cells from immunized mice exposed to all the peptides except GRA7<sub>134-142</sub>. Figure <span class="InternalRef"><a href="#Fig7_50">7a</a></span> shows the representative data of IFN-γ spot formation from the four immunization groups which were stimulated by individual peptides. The inclusion of the newly identified peptides thus had potential to enhance immunogenicity in transgenic HLA-A*1101 mice.<figure xmlns="" class="Figure" id="Fig7_50"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                                        <a target="_blank" rel="noopener" href="https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig7_HTML.jpg"><img class="c-lazy-image u-js-shown" src="https://media.springernature.com/lw5/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig7_HTML.jpg" alt="Figure 7" data-lazy-load="true" data-src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig7_HTML.jpg"><img src="https://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1745-7580-6-12/MediaObjects/12996_2010_Article_50_Fig7_HTML.jpg" alt="Figure 7"></img></a>
                                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 7</span>
                                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Addition of peptides to pool robustly protects HLA-A*1101 mice against Type II parasite challenge</strong>. HLA-A*1101 transgenic mice were immunized with PBS (controls) or peptide pool with PADRE and Pam<sub xmlns="http://www.w3.org/1999/xhtml">2</sub>Cys in GLA-SE. Splenic T cells were isolated 10-14 days post immunization and exposed to each peptide in an <em class="EmphasisTypeItalic">ex vivo</em> IFN-γ ELISpot assay (Figure 7a). HLA-A*1101 transgenic mice immunized with peptide pool and adjuvants were protected compared with control mice inoculated with PBS when they were challenged with 10,000 Pru (Fluc)-<em class="EmphasisTypeItalic">T. gondii</em> luciferase expressing parasites (Figure 7b). Mice were immunized and in a subgroup immune function was studied at the same time as the challenge shown was performed. Differences between control and immunized mice were significant (p &lt; 0.0064 using natural log transformed data and two-sample t test).</p>
                                    </div></figcaption></figure>
                                    </div>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mice were challenged 2 weeks after the last immunization. They were imaged five days after they had been challenged with 10,000 Pru (Fluc) using a Xenogen <em xmlns="" class="EmphasisTypeItalic">in vivo</em> imaging system. As shown in the initial experiment in Figure <span class="InternalRef"><a href="#Fig7_50">7b</a></span>, the numbers of luciferase expressing parasites in immunized HLA-A*1101 mice were significantly reduced compared to the numbers of parasites in unimmunized mice. Results were mean[standard deviation](median) 2.5[<span class="CitationRef"><a href="#CR1_50" data-toggle="citation">1</a></span>](2.3) million for nonimmunized mice versus.6[.3](.5)million for immunized mice. With natural log transformed data, mean[standard deviation} was.9 [.4] for nonimmunized mice versus -.6[.4] for immunized mice; p &lt; 0.0025 using natural log transformed data and two-sample t test.</p>
                                </section><section id="Sec10_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Population Coverage prediction</h3>
                                    <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">An algorithm was developed to calculate projected population coverage of a T cell epitope-based vaccine using MHC binding or T cell restriction data and HLA gene frequencies[<span class="CitationRef"><a href="#CR17_50" data-toggle="citation">17</a></span>]. We used this web-based tool <span class="ExternalRef"><a href="http://www.iedb.org/" target="_blank" class="ext-link"><span class="RefSource">http://www.iedb.org/</span></a></span> to predict population coverage of these HLA-A03 supertype peptide epitopes-based vaccine. The population coverage calculation results in Table <span class="InternalRef"><a href="#Tab4_50">4</a></span> indicate that such coverage is varied in different geographic regions. The HLA-A03 supertype molecules that present these peptides would be expected to be present in 28.90% population in Australia; 41.46% in Europe; 11.29% in North America; 18.86% in North-East Asia; 37.73% in South-East Asia; 34.29% in South-West Asia; 34.09% in Oceania; 27.32% in North Africa; 13.14% in Sub-Saharan Africa and 22.13% for others. The average population coverage by the HLA-A03 supertype is 24.51% ± 12.06%.<figure xmlns="" id="Tab4_50" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 4</span>
                                        <p xmlns="" class="SimplePara">Prediction of population coverage</p>
                                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col><col><col><col></colgroup><thead><tr class="header"><th>&nbsp;</th><th colspan="3"><p xmlns="" class="SimplePara">Class I</p></th></tr><tr class="header"><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">Population/Area</strong>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">Coverage</strong>
                                        <sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">a</strong>
                                        </sup>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">Average hit</strong>
                                        <sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">b</strong>
                                        </sup>
                                    </p></th><th><p xmlns="" class="SimplePara">
                                        <strong class="EmphasisTypeBold">PC90</strong>
                                        <sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">c</strong>
                                        </sup>
                                    </p></th></tr></thead><tbody><tr class="noclass"><td><p xmlns="" class="SimplePara">Australia</p></td><td><p xmlns="" class="SimplePara">28.90%</p></td><td><p xmlns="" class="SimplePara">1.30</p></td><td><p xmlns="" class="SimplePara">0.14</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">Europe</p></td><td><p xmlns="" class="SimplePara">41.46%</p></td><td><p xmlns="" class="SimplePara">0.98</p></td><td><p xmlns="" class="SimplePara">0.17</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">North Africa</p></td><td><p xmlns="" class="SimplePara">27.32%</p></td><td><p xmlns="" class="SimplePara">0.45</p></td><td><p xmlns="" class="SimplePara">0.14</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">North America</p></td><td><p xmlns="" class="SimplePara">11.29%</p></td><td><p xmlns="" class="SimplePara">0.24</p></td><td><p xmlns="" class="SimplePara">0.11</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">North-East Asia</p></td><td><p xmlns="" class="SimplePara">18.86%</p></td><td><p xmlns="" class="SimplePara">0.74</p></td><td><p xmlns="" class="SimplePara">0.12</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">Oceania</p></td><td><p xmlns="" class="SimplePara">34.09%</p></td><td><p xmlns="" class="SimplePara">1.69</p></td><td><p xmlns="" class="SimplePara">0.15</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">Other</p></td><td><p xmlns="" class="SimplePara">22.13%</p></td><td><p xmlns="" class="SimplePara">0.59</p></td><td><p xmlns="" class="SimplePara">0.13</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">South America</p></td><td><p xmlns="" class="SimplePara">0.42%</p></td><td><p xmlns="" class="SimplePara">0.00</p></td><td><p xmlns="" class="SimplePara">0.10</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">South-East Asia</p></td><td><p xmlns="" class="SimplePara">37.73%</p></td><td><p xmlns="" class="SimplePara">1.84</p></td><td><p xmlns="" class="SimplePara">0.16</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">South-West Asia</p></td><td><p xmlns="" class="SimplePara">34.29%</p></td><td><p xmlns="" class="SimplePara">1.09</p></td><td><p xmlns="" class="SimplePara">0.15</p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeUnderline">Sub-Saharan Africa</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeUnderline">13.14%</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeUnderline">0.23</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeUnderline">0.12</span>
                                    </p></td></tr><tr class="noclass"><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeBoldUnderline">Average (Standard deviation)</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeBoldUnderline">24.51% (12.06%)</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeBoldUnderline">0.83 (0.58)</span>
                                    </p></td><td><p xmlns="" class="SimplePara">
                                        <span class="EmphasisTypeBoldUnderline">0.14 (0.02)</span>
                                    </p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">a</strong>
                                        </sup> projected population coverage for SAG1224-232 (KSFKDILPK); GRA6164-172 (AMLTAFFLR);GRA7134-142 (RSFKDLLKK); SAG2C13-21 (STFWPCLLR); SPA250-258(SSAYVFSVK); SPA89-98 (AVVSLLRLLK).</p>
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">b</strong>
                                        </sup> average number of epitope hits/HLA combinations recognized by the population</p>
                                        <p xmlns="" class="SimplePara"><sup xmlns="http://www.w3.org/1999/xhtml">
                                            <strong xmlns="" class="EmphasisTypeBold">c</strong>
                                        </sup> minimum number of epitope hits/HLA combinations recognized by 90% of the population.</p>
                                        <p xmlns="" class="SimplePara">Population coverage was calculated using the analysis resource available at the IEDB <span xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://www.iedb.org" target="_blank" class="ext-link"><span class="RefSource">http://www.iedb.org</span></a></span>, and as described by Bui et al. 2006 [PMID 16545123]. Calculations are based on HLA genotypic frequencies obtained from the dbMHC database <span xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://www.ncbi.nlm.nih.gov/mhc/" target="_blank" class="ext-link"><span class="RefSource">http://www.ncbi.nlm.nih.gov/mhc/</span></a></span>. Population coverage reflects the fraction of individuals predicted to respond the epitope set inclusive of SAG1224-232 (KSFKDILPK), GRA6164-172 (AMLTAFFLR), GRA7134-142 (RSFKDLLKK), SAG2C13-21 (STFWPCLLR), SPA250-258 (SSAYVFSVK), and SPA89-98 (AVVSLLRLLK). The value shown corresponds to the average coverage across 11 different major geographical areas.</p>
                                    </div></figure>
                                    </div>
                                </section></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec11_50" class="Section1 RenderAsSection1 c-section"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Discussion" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Discussion">Discussion</a></h2><div class="js-CollapseSection CollapseSection c-section__content" id="Discussion" data-test="collapse-section"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In this study, we first evaluated immunization of HLA-A*1101 transgenic mice with either mixtures of peptides or lipopeptides derived from three identified <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> specific HLA-A*1101 restricted CD8<sup>+</sup> T cell epitopes emulsified in 3-deacylated monophosphoryl lipid A(GLA-SE) adjuvant. Immunizations of transgenic mice with a mixture of CD8<sup>+</sup> epitope peptide pools plus PADRE and adjuvants were able to induce splenocyte to produce IFN-γ and to protect against challenge with high numbers of Type II parasites.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Conjugation of CD8<sup>+</sup> T cell determinants to lipid groups is known to enhance specific cell-mediated responses to target antigens in experimental animals and humans[<span class="CitationRef"><a href="#CR25_50" data-toggle="citation">25</a></span><span>, <span class="CitationRef"><a href="#CR26" data-toggle="citation">26</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation">27</a></span>, <span class="CitationRef"><a href="#CR28" data-toggle="citation">28</a></span>, </span><span class="CitationRef"><a href="#CR29_50" data-toggle="citation">29</a></span>], although mechanisms whereby immunity is achieved remains poorly understood. Lipopeptides hold several advantages over other conventional vaccine formulations; for instance, they are self-adjuvanting and display none of the toxicity-associated side effects of other Th1-inducing adjuvant systems. In our work, transgenic mice that were immunized with three short lipopeptide vaccines had T cells that produced IFN-γ. Among them the lipopeptide vaccine formulated with KS9 or AM9 stimulated higher IFN-γ production than the lipopeptide vaccine formulated with RS9. Unexplained and variable responses have been observed to high affinity binding peptides in other models, e.g., studies of Livingstone, Alexander, Sette et al with Lassa fever virus. It will be of interest to better understand possible mechanisms for such lack of response in future studies. However, the lipopeptides with three epitope peptides linked together with alanine spacers did not stimulate an IFN-γ response by splenocytes from immunized mice when the splenocytes subsequently were exposed to each of the peptides <em xmlns="" class="EmphasisTypeItalic">in vitro</em>. The reason why the lipopeptides with the three linked peptides did not work well in the transgenic mice might be related to a frame shift caused by the linkers that altered the response to the original peptides rather than the alanines functioning for the intended purpose of introducing a cleavage motif. The three linker "AAA'' between the peptides had previously been demonstrated in other systems to result in sensitization to each linked peptide. However, surprisingly, it did not appear to work well herein.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Because the three linked peptides in the lipopeptide formulation were not effective and we had found that a mixture of the components with a single peptide was as or more robust than the lipopeptide, we tried this approach with the three peptides that had been included in the linked lipopeptide with the universal helper CD4<sup>+</sup> T cell peptide, PADRE, and adjuvants as described below. The response was robust both <em xmlns="" class="EmphasisTypeItalic">in vitro</em> and <em xmlns="" class="EmphasisTypeItalic">in vivo</em> (Figures <span class="InternalRef"><a href="#Fig4_50">4</a></span> and <span class="InternalRef"><a href="#Fig5_50">5</a></span>).</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Some studies have shown palmitoylated lipopeptide constructs to elicit long-lived, protective cellular responses against a variety of pathogens, including Hepatitis B virus (HBV), influenza virus, and <em xmlns="" class="EmphasisTypeItalic">Plasmodium falciparum</em> [<span class="CitationRef"><a href="#CR25_50" data-toggle="citation">25</a></span><span>, <span class="CitationRef"><a href="#CR26" data-toggle="citation">26</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation">27</a></span>, <span class="CitationRef"><a href="#CR28" data-toggle="citation">28</a></span>, </span><span class="CitationRef"><a href="#CR29_50" data-toggle="citation">29</a></span>]. Our work herein shows that mice immunized with mixture of CD8<sup>+</sup> and CD4<sup>+</sup> eliciting peptides and lipid Pam<sub>2</sub>Cys emulsified in GLA-SE elicited higher IFN-γ production than mice immunized with lipopeptides constructed with the same components of CD4<sup>+</sup> and CD8<sup>+</sup> eliciting peptides, and Pam<sub>2</sub>Cys. The approach using cocktails of non-covalently linked lipid mixed to helper T lymphocytes(HTL) and CD8<sup>+</sup>T cell (cytolytic T lymphcyte[CTL] and IFN-γ eliciting) epitopes for simultaneous induction of multiple CD8<sup>+</sup>T specificities would have significant advantages in terms of ease of vaccine development.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">HTL responses are crucial for the development of CD8<sup>+</sup>T responses, at least in the case of lipidated covalently or non-covalently linked HTL-CTL epitope constructs formulated in PBS. Several previous studies have illustrated a role for CD4<sup>+</sup> responses for development of CD8<sup>+</sup>CTL responses, both in humans and in experimental animals[<span class="CitationRef"><a href="#CR30_50" data-toggle="citation">30</a></span><span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation">31</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation">32</a></span>, <span class="CitationRef"><a href="#CR33" data-toggle="citation">33</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation">34</a></span>, </span><span class="CitationRef"><a href="#CR35_50" data-toggle="citation">35</a></span>]. The inclusion of PADRE, a synthetic peptide that binds promiscuously to variants of the human MHC class II molecule DR and is effective in mice, also augmented CD8<sup>+</sup> T cell effector functions by inducing CD4<sup>+</sup> T helper cells[<span class="CitationRef"><a href="#CR30_50" data-toggle="citation">30</a></span><span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation">31</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation">32</a></span>, <span class="CitationRef"><a href="#CR33" data-toggle="citation">33</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation">34</a></span>, </span><span class="CitationRef"><a href="#CR35_50" data-toggle="citation">35</a></span>]. Both CD4<sup>+</sup> and CD8<sup>+</sup> epitopes were targeted in order to drive a protective immune response[<span class="CitationRef"><a href="#CR34_50" data-toggle="citation">34</a></span>, <span class="CitationRef"><a href="#CR35_50" data-toggle="citation">35</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Adjuvanting antigens contributes to the success of vaccination. An example herein is that 3-deacylated monophosphoryl lipid A(GLA-SE), a detoxified derivative of the lipopolysaccharide (LPS) from <em xmlns="" class="EmphasisTypeItalic">Salmonella minnesota R595</em> was a potent adjuvant. This GLA-SE is a novel adjuvant which was formulated in an emulsion[<span class="CitationRef"><a href="#CR21_50" data-toggle="citation">21</a></span><span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation">22</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation">23</a></span>, </span><span class="CitationRef"><a href="#CR24_50" data-toggle="citation">24</a></span>]. This is a Toll-like receptor 4 (TLR4) agonist that is a potent activator of Th1 responses [<span class="CitationRef"><a href="#CR21_50" data-toggle="citation">21</a></span><span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation">22</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation">23</a></span>, </span><span class="CitationRef"><a href="#CR24_50" data-toggle="citation">24</a></span>]. It has been used as an adjuvant in human vaccine trials for several infectious disease and malignancy indications. It has been very effective as an adjuvant providing CD4<sup>+</sup> T cell help for immunizations against other protozoan infections such as leishmaniasis [<span class="CitationRef"><a href="#CR21_50" data-toggle="citation">21</a></span><span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation">22</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation">23</a></span>, </span><span class="CitationRef"><a href="#CR24_50" data-toggle="citation">24</a></span>]. In our study, a robust response was observed when GLA-SE was included in preparation for immunization of mice. Pam<sub>2</sub>Cys (S-[2,3-bis(palmitoyloxy)propyl]cysteine) is a lipid component of macrophage-activating lipopeptide. Pam<sub>2</sub>Cys binds to and activates dendritic cells by engagement of Toll-like receptor 2 (TLR-2)[<span class="CitationRef"><a href="#CR24_50" data-toggle="citation">24</a></span>]. Toll-like receptors (TLRs) function as pattern-recognition receptors in mammals[<span class="CitationRef"><a href="#CR36_50" data-toggle="citation">36</a></span>]. We have found that both TLR2 and TLR4 receptors participate in human host defense against <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> infection through their activation by GPIs and GIPLs(Melo, Hargrave, Miller, Blackwell, Gazinelli, McLeod et al, in preparation, 2010). TLR2 and TLR4 likely work together with other MyD88-dependent receptors, including other TLRs, to elicit an effective host response against <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> infection[<span class="CitationRef"><a href="#CR36_50" data-toggle="citation">36</a></span>]. In our study, there was a slightly more robust response observed when Pam<sub>2</sub>Cys was co-administered for some peptides, but not all of them.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The goal of the present study was to identify HLA-restricted epitopes from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> and evaluate whether they could provide protection against parasite challenge measured as protection against a luciferase producing Type ll parasite using a Xenogen camera system. In the future, additional more detailed studies involving analyses over longer times, other strains of the parasite and challenge with life cycle stages, evaluation of multiple organs including eye and brain, studies of protection in congenital infections, comparisons of delivery of these peptides as DNA encoding them versus other formulations. This future work will follow up and extend these intitial studies of reduction of parasite burden seen in Figures <span class="InternalRef"><a href="#Fig5_50">5</a></span> and <span class="InternalRef"><a href="#Fig7_50">7</a></span>.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Various peptide-based approaches to induction of IFN-γ responses were evaluated as part of ongoing efforts to develop immunosense vaccines for use in humans with each of the supermotifs which would in total include more that 99% of the human population worldwide. Robust protection was achieved in the HLA-A*1101 transgenic mice challenged with Type II parasites following immunizations. In order to identify additional peptides from <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> that were present in tachyzoites or bradyzoites[<span class="CitationRef"><a href="#CR37_50" data-toggle="citation">37</a></span>, <span class="CitationRef"><a href="#CR38_50" data-toggle="citation">38</a></span>] or sporozoites of Type I and II strains and elicited IFN-γ from HLA-A03<sup>+</sup> supertype (which includes the HLA*1011 allele) restricted CD8<sup>+</sup> T cells, bioinformatic algorithms were utilized to identify novel, <em xmlns="" class="EmphasisTypeItalic">T. gondii</em>-derived, epitopes restricted by the HLA-A03 supertype. Then PBMC cells were tested to determine whether the peptides elicited IFN-γ from human CD8<sup>+</sup> T cells from seropositive persons. This was intended to collectively provide broad coverage for the human population with HLA-A03 supertype worldwide. The additional peptides we identified as immunogenic for human peripheral blood cells were also robust in eliciting IFN-γ from splenocytes of HLA-A*1101 mice and protection when used to immunize these mice. These findings will facilitate development of an immunosense epitope-based vaccine for human use.</p></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec12_50" class="Section1 RenderAsSection1 c-section"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Conclusion" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Conclusion">Conclusion</a></h2><div class="js-CollapseSection CollapseSection c-section__content" id="Conclusion" data-test="collapse-section"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">A human immunome-based and parasite genome based bioinformatices approach was used to define candidate HLA-A03 supertype restricted peptides. Immunogenicity of a group of <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> HLA-A03 supertype restricted peptides, and therefore the proteins from which they are derived, for immune humans and HLA-A*1101 transgenic mice was demonstrated. These peptides elicit interferon-γ production by human CD8<sup>+</sup>T cells. They also elicit interferon γ production by mouse splenocytes when utilized to immunize HLA-A*1101 transgenic mice with a lipopeptide with a universal CD4<sup>+</sup> T cell eliciting epitope, PADRE, or in peptide pools with PADRE, Pam<sub>2</sub>Cys and GLA-SE, a novel adjuvant. Immunization studies demonstrate the need for and the efficacy of adjuvants in immunization of these HLA transgenic mice. Immunogenic peptides included KSFKDILPK (SAG1<sub>224-232</sub>); AMLTAFFLR (GRA6<sub>164-172</sub>); and RSFKDLLKK (GRA7<sub>134-142</sub>); STFWBCLLR (SAG2C<sub>13-21</sub>); SSAYVFSVK (SPA<sub>250-258</sub>); and AVVSLLRLLK (SPA<sub>89-98</sub>). The studies herein provide a foundation for immunosense based vaccines to prevent toxoplasmosis in those with the HLA-A03 supertype and information about how they can be adjuvanted.</p></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec13_50" class="Section1 RenderAsSection1 c-section"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Methods" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Methods">Methods</a></h2><div class="js-CollapseSection CollapseSection c-section__content" id="Methods" data-test="collapse-section"><section id="Sec14_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Peptides and lipopeptides</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">HLA-A03 supertype CD8<sup>+</sup> T cell epitopes included: KSFKDILPK (SAG1<sub>224-232</sub>), AMLTAFFLR (GRA6<sub>164-172</sub>), and RSFKDLLKK (GRA7<sub>134-142</sub>). PADRE (AKFVAAWTLKAAA) was the universal CD4 helper peptide used in vaccine constructs. Pam<sub>2</sub>Cys (Pam<sub>2</sub>-KSS) also was included. Lipopeptide constructs used in this study are shown in Figure <span class="InternalRef"><a href="#Fig1_50">1</a></span>. Peptides and lipopeptides were synthesized by Synthetic Biomolecules, San Diego at &gt; 90% purity. Additional HLA-A03 supertype bound peptides and their initial grouping into pools for <em xmlns="" class="EmphasisTypeItalic">in vitro</em> studies are shown in Tables <span class="InternalRef"><a href="#Tab1_50">1</a></span> and <span class="InternalRef"><a href="#Tab2_50">2</a></span>. A TLR4 agonist, a GLA-SE adjuvant, was synthesized by the Infectious Diseases Research Institute (Seattle, Washington) as a stable oil-in-water emulsion. AMLTAFFLR (GRA6 <sub>164-172</sub>) and additional new peptides were first dissolved in DMSO and then diluted in PBS.</p>
                                </section><section id="Sec15_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Mice</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">HLA-A*1101/K<sup>b</sup> transgenic mice were produced at Pharmexa-Epimmune (San Diego, CA) and bred at the University of Chicago. These HLA-A*1101/K<sup>b</sup> transgenic mice express a chimeric gene consisting of the 1 and 2 domains of HLA-A*1101 and the 3 domain of H-2K<sup>b</sup>, and were created on a C57BL/6 background. For each test, we used 4-5 mice for each group. Each experiment was repeated 2 to 3 times. Experiments in Figure <span class="InternalRef"><a href="#Fig7_50">7b</a></span> were performed including a subgroup analyzed for immune response in parallel with a subgroup in the challenge shown. All studies were conducted with approval of the Institutional Animal Care and Use Committee at the University of Chicago.</p>
                                </section><section id="Sec16_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Parasites</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Transgenic <em xmlns="" class="EmphasisTypeItalic">T. gondii</em> used for <em xmlns="" class="EmphasisTypeItalic">in vivo</em> challenges was derived from Type II Prugniaud (Pru) strain and expresses the firefly luciferase (FLUC) gene constitutively by tachyzoites and bradyzoites. It was created, and kindly provided by S. Kim, J. Boothroyd and J. Saeij(Stanford University) and was maintained and utilized as previously described[<span class="CitationRef"><a href="#CR18_50" data-toggle="citation">18</a></span>, <span class="CitationRef"><a href="#CR37_50" data-toggle="citation">37</a></span>, <span class="CitationRef"><a href="#CR39_50" data-toggle="citation">39</a></span>].</p>
                                </section><section id="Sec17_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Immunizations and challenge</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">To evaluate peptide immunogenicity, HLA-A*1101 transgenic mice were inoculated subcutaneously (s.c.) at the base of the tail using a 30-gauge needle with single peptides or a mixture of CD8<sup>+</sup> T cell peptides (50 μg of each peptide per mouse) and PADRE (AKFVAAWTLKAAA) emulsified in 20 μg of GLA-SE (TLR4 agonist) with or without Pam<sub>2</sub>Cys. Pam<sub>2</sub>Cys concentration was 5 mg/ml. For immunization with lipopeptides, HLA-A*1101 mice received 20 nmol lipopeptide dissolved in PBS or emulsified in GLA-SE. As controls, mice were injected with PBS or PBS/GLA-SE. For the lipopeptide immunizations, the mice were vaccinated twice at intervals of three weeks. For the peptide immunizations, mice were immunized three times at intervals of two weeks. For challenge studies, mice were immunized with peptide emulsions and challenged intraperitoneally (i.p.) 14 days post-immunization using 10,000 Type II parasites.</p>
                                </section><section id="Sec18_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading"><em class="EmphasisTypeItalic">In vivo</em> bioluminescence imaging</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mice infected with 10,000 Pru-FLUC tachyzoites were imaged 7 days post-challenge using the <em xmlns="" class="EmphasisTypeItalic">in vivo</em> imaging system (IVIS; Xenogen, Alameda, CA). Mice were injected i.p. with 200 μl of D-luciferin, anesthetized in an O<sub>2</sub>-rich induction chamber with 2% isoflurane, and imaged after 12 minutes. Photonic emissions were assessed using Living image<sup>®</sup> 2.20.1 software (Xenogen). Data are presented as pseudocolor representations of light intensity and mean photons/region of interest (ROI). All mouse experiments were repeated at least twice. There were 4-5 mice for each group. In the experiment in Figure <span class="InternalRef"><a href="#Fig7_50">7b</a></span> a subgroup of mice was used for studying immune response in parallel with the subgroup in the challenge shown.</p>
                                </section><section id="Sec19_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">ELISpot assay</h3>
                                    <section id="Sec20_50" class="Section3 RenderAsSection3">
                                        <h4 class="Heading">Murine splenocytes</h4>
                                        <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mice were euthanized 7 to 14 days after immunization. Spleens were harvested, pressed through a 70 μm screen to form a single-cell suspension, and depleted of erythrocytes with AKC lysis buffer (160 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 100 M EDTA). Splenocytes were washed twice with Hank's Balanced Salt Solution (HBSS) and resuspended in complete RPMI medium (RPMI-1640 supplemented with 2 mM L-GlutaMax [Invitrogen], 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 50 M -mercaptoethanol, and 10% FCS) before they were used in subsequent <em xmlns="" class="EmphasisTypeItalic">in vitro</em> assays. Peptide concentration was 20 mg/ml and 0.20 μl was used per well. ELISpot assays with murine splenocytes were performed using α-mouse IFN-γ mAb (AN18) and biotinylated α-mouse IFN-γ mAb (R4-6A2) as the cytokine-specific capture antibodies. Antibodies were monoclonal antibodies. 5 × 10<sup>5</sup> splenocytes were plated per well.</p>
                                    </section>
                                    <section id="Sec21_50" class="Section3 RenderAsSection3">
                                        <h4 class="Heading">Human PBMC</h4>
                                        <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">PBMC were obtained, HLA haplotype was determined, and they were processed and cryopreserved as described[<span class="CitationRef"><a href="#CR18_50" data-toggle="citation">18</a></span>]. ELISpot assays with human PBMCs were similar to those with murine splenocytes but used α-human IFN-γ mAb (1-D1K) with biotinylated α-human IFN-γ mAb (7B6-1) with 2 × 10<sup>5</sup> PBMCs per well. All antibodies and reagents used for ELISpot assays were from Mabtech (Cincinnati, OH). Antibodies were monoclonal antibodies. Both murine and human cells were plated in at least 3 replicate wells for each condition. Results were expressed as number of spot forming cells (SFCs) per 10<sup>6</sup> PBMCs or per 10<sup>6</sup> murine splenocytes.</p>
                                    </section>
                                </section><section id="Sec22_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Bioinformatic predictions and MHC-peptide binding assays</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Protein sequences derived from GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, and MIC were analyzed for CD8<sup>+</sup> T cell epitopes based on predicted binding affinity to HLA-A03 supertype molecules using ARB algorithms from immunoepitope database (IEDB) <span class="ExternalRef"><a href="http://www.immuneepitope.org" target="_blank" class="ext-link"><span class="RefSource">http://www.immuneepitope.org</span></a></span>[<span class="CitationRef"><a href="#CR40_50" data-toggle="citation">40</a></span>, <span class="CitationRef"><a href="#CR41_50" data-toggle="citation">41</a></span>]. A total of 34 unique peptides IC<sub>50</sub> &lt; 50 nM of all ranked nonameric peptides were selected. All protein sequences were from ToxoDB 5.1.</p>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Quantitative assays to measure binding of peptides to HLA class I molecules are based on inhibition of binding of radiolabeled standard peptide. Assays were as described[<span class="CitationRef"><a href="#CR42_50" data-toggle="citation">42</a></span>]. Concentration of peptide yielding 50% inhibition of binding of radiolabeled probe peptide (IC<sub>50</sub>) was calculated. Under conditions used, where [radiolabeled probe] &lt; [MHC] and IC<sub>50</sub> ≥ [MHC], measured IC<sub>50</sub> values are reasonable approximations of true <em xmlns="" class="EmphasisTypeItalic">K</em>
                                        <sub>d</sub> values[<span class="CitationRef"><a href="#CR43_50" data-toggle="citation">43</a></span>, <span class="CitationRef"><a href="#CR44_50" data-toggle="citation">44</a></span>].</p>
                                </section><section id="Sec23_50" class="Section2 RenderAsSection2">
                                    <h3 class="Heading">Statistical analyses</h3>
                                    <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Statistical analyses for all <em xmlns="" class="EmphasisTypeItalic">in vitro</em> assays were performed using 2-tailed student's T test. Natural log transformed data and two-sample t test were used to analyze data shown in Figures <span class="InternalRef"><a href="#Fig5_50">5</a></span> and <span class="InternalRef"><a href="#Fig7_50">7b</a></span>. Two-tailed <em xmlns="" class="EmphasisTypeItalic">P</em> values &lt; 0.05 were considered statistically significant. Peptides were considered immunogenic in mice if they induced IFN-γ spot formation from immunized mice that were significant (<em xmlns="" class="EmphasisTypeItalic">P</em> &lt; 0.05) compared with spot formation from control mice. All mouse experiments were repeated at least twice. There were 4-5 mice for each group. The experiment in Figure <span class="InternalRef"><a href="#Fig7_50">7b</a></span> determined immune response and imaged mice in parallel.</p>
                                </section></div></section>
                                <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 c-section" data-test="declarations-section" id="Decs"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Declarations" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Declarations">Declarations</a></h2><div class="js-CollapseSection CollapseSection c-section__content" data-test="collapse-section" id="Declarations"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Acknowledgments"><h3 xmlns="" class="Heading">Acknowledgements</h3><p xmlns="" class="SimplePara">We thank C. Oseroff for helpful suggestions, K. Wroblewski for assistance with statistical analyses, P. Terasaki for HLA-typing, J. Boothroyd, J. Saeij, and S. Kim for the luciferase expressing parasite, N. Blanchard and N. Shastri for sharing pre-publication data and other suggestions, S. Reed for adjuvants, and families and collaborating physicians/scientists in the NCCCTS who made this work possible. We gratefully acknowledge support of this work by gifts from the Fin Charity Trust, R. Blackfoot, R. Thewind, A. Akfortseven, S. Gemma, S. Jackson, A.K. Bump, the Rooney Aldens, the Dominique Cornwell and Peter Mann Family Foundation, the Alison F. Engel and Peter E. Engel Charitable Fund, Jack M. and Donna L. Greenberg Philanthropic Fund, the Morel, Rosenstein, Kapnick, Taub, Daley-Conroy, Schilling, Greenberg, Dunphy, Zorek, Munroe, and Kiewit families, and Toxoplasmosis Research Institute. This work also was supported by DMID-NIAID U01 AI77887, UR01 AI0433228, R01 AI071319, (RM), the China scholarship Council(CH), a grant from the National Natural Science Foundation Project of China (No. 30700693)(CH), and The Research to Prevent Blindness Foundation(RM). The funding sources had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.</p></div><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Competing interests</h3><p xmlns="" class="SimplePara">The authors declare that they have no competing interests.</p></aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Authors' contributions</h3><p xmlns="" class="SimplePara">All authors contributed to the work in this manuscript. HC, EJM, WHW, JS, JA, AS, AM, and RM designed and/or performed experiments, provided key reagents, revised the manuscript for significant context, and reviewed the manuscript as submitted. HC, EJM, JS, JA, AM, and RM wrote the entire manuscript and edited drafts of the manuscript for significant content. All authors read and approved the final version submitted.</p></aside></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 c-section Affiliations" id="Aff"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Author-Affiliations" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Author-Affiliations">Authors’ Affiliations</a></h2><div class="js-CollapseSection CollapseSection c-section__content c-section__content" data-test="collapse-section" id="Author-Affiliations"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff1_50"><span class="AffiliationNumber">(1)</span><div class="AffiliationText">Department of Surgery(Ophthalmology and Visual Sciences), The University of Chicago, 60637&nbsp;Chicago, Illinois, USA</div></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff2_50"><span class="AffiliationNumber">(2)</span><div class="AffiliationText">Department of Parasitology, School of Medicine, Shandong University, 250012&nbsp;Jinan, Shandong, PR China</div></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff3_50"><span class="AffiliationNumber">(3)</span><div class="AffiliationText">Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 92037&nbsp;La Jolla, California, USA</div></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff4_50"><span class="AffiliationNumber">(4)</span><div class="AffiliationText">Pharmexa-Epimmune, 92121&nbsp;San Diego, California, USA</div></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff5_50"><span class="AffiliationNumber">(5)</span><div class="AffiliationText">Synthetic Biomolecules, 92121&nbsp;San Diego, California, USA</div></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Affiliation" id="Aff6_50"><span class="AffiliationNumber">(6)</span><div class="AffiliationText">Departments of Surgery (Ophthalmology and Visual Sciences) and Pediatrics (Infectious Disease), Committees on Immunology, Molecular Medicine, and Genetics, Institute of Genomics and Systems Biology, and The College, The University of Chicago, Chicago, Illinois&nbsp;60637, USA</div></div></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 c-section SectionTypeMaterialsAndMethods" id="Bib1_50"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#References" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="References">References</a></h2><div class="js-CollapseSection CollapseSection c-section__content" data-test="collapse-section" id="References"><ol class="BibliographyWrapper"><li class="Citation"><cite class="CitationContent" id="CR1_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Remington JS, McLeod R, Thulliez P, Wilson C, Desmonts G: <strong class="EmphasisTypeBold">Congenital Toxoplasmosis.</strong> In <em class="EmphasisTypeItalic">Infectious Diseases of the Fetus and Newborn Infant</em>. 7th edition. Edited by: Remington JS, Klein J, Wilson C. Philadelphia: W.B Saunders; 2010:in press.</span><span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Congenital%20Toxoplasmosis&amp;author=JS.%20Remington&amp;author=R.%20McLeod&amp;author=P.%20Thulliez&amp;author=C.%20Wilson&amp;author=G.%20Desmonts&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR2_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">McLeod R, Mack D, Foss R, Boyer K, Withers S, Levin S, Hubbel J: <strong class="EmphasisTypeBold">Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis.</strong>
                  <em class="EmphasisTypeItalic">Antimicrob Ag Chemother</em> 1992, <strong class="EmphasisTypeBold">36:</strong>1040–8.</span><span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Levels%20of%20pyrimethamine%20in%20sera%20and%20cerebrospinal%20and%20ventricular%20fluids%20from%20infants%20treated%20for%20congenital%20toxoplasmosis&amp;author=R.%20McLeod&amp;author=D.%20Mack&amp;author=R.%20Foss&amp;author=K.%20Boyer&amp;author=S.%20Withers&amp;author=S.%20Levin&amp;author=J.%20Hubbel&amp;journal=Antimicrob%20Ag%20Chemother&amp;volume=36&amp;pages=1040-8&amp;publication_year=1992"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR3_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H: <strong class="EmphasisTypeBold">Why prevent, diagnose and treat congenital toxoplasmosis?</strong>
                  <em class="EmphasisTypeItalic">Mem Inst Oswaldo Cruz</em> 2009, <strong class="EmphasisTypeBold">104:</strong>320–344.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1590/S0074-02762009000200029"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19430661"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Why%20prevent%2C%20diagnose%20and%20treat%20congenital%20toxoplasmosis%3F&amp;author=R.%20McLeod&amp;author=F.%20Kieffer&amp;author=M.%20Sautter&amp;author=T.%20Hosten&amp;author=H.%20Pelloux&amp;journal=Mem%20Inst%20Oswaldo%20Cruz&amp;volume=104&amp;pages=320-344&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR4_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, Wolters C, Stein L, Stein M, Schey W, Remington J, Meier P, Johnson D, Heydemann P, Holfels E, Withers S, Mack D, Brown C, Patton D, McLeod R: <strong class="EmphasisTypeBold">Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial.</strong>
                  <em class="EmphasisTypeItalic">Clin Infect Dis</em> 1994, <strong class="EmphasisTypeBold">18:</strong>38–72.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8054436"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Early%20and%20longitudinal%20evaluations%20of%20treated%20infants%20and%20children%20and%20untreated%20historical%20patients%20with%20congenital%20toxoplasmosis%3A%20the%20Chicago%20Collaborative%20Treatment%20Trial&amp;author=J.%20McAuley&amp;author=KM.%20Boyer&amp;author=D.%20Patel&amp;author=M.%20Mets&amp;author=C.%20Swisher&amp;author=N.%20Roizen&amp;author=C.%20Wolters&amp;author=L.%20Stein&amp;author=M.%20Stein&amp;author=W.%20Schey&amp;author=J.%20Remington&amp;author=P.%20Meier&amp;author=D.%20Johnson&amp;author=P.%20Heydemann&amp;author=E.%20Holfels&amp;author=S.%20Withers&amp;author=D.%20Mack&amp;author=C.%20Brown&amp;author=D.%20Patton&amp;author=R.%20McLeod&amp;journal=Clin%20Infect%20Dis&amp;volume=18&amp;pages=38-72&amp;publication_year=1994"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR5_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Sautter M, Remington J, Meier P, McLeod R, Toxoplasmosis Study Group: <strong class="EmphasisTypeBold">Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life.</strong>
                  <em class="EmphasisTypeItalic">Am J Ophthalmol</em> 2008, <strong class="EmphasisTypeBold">146:</strong>375–84.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/j.ajo.2008.04.033"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18619570"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Longitudinal%20study%20of%20new%20eye%20lesions%20in%20children%20with%20toxoplasmosis%20who%20were%20not%20treated%20during%20the%20first%20year%20of%20life&amp;author=L.%20Phan&amp;author=K.%20Kasza&amp;author=J.%20Jalbrzikowski&amp;author=AG.%20Noble&amp;author=P.%20Latkany&amp;author=A.%20Kuo&amp;author=W.%20Mieler&amp;author=S.%20Meyers&amp;author=P.%20Rabiah&amp;author=K.%20Boyer&amp;author=C.%20Swisher&amp;author=M.%20Mets&amp;author=N.%20Roizen&amp;author=S.%20Cezar&amp;author=M.%20Sautter&amp;author=J.%20Remington&amp;author=P.%20Meier&amp;author=R.%20McLeod&amp;journal=Am%20J%20Ophthalmol&amp;volume=146&amp;pages=375-84&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR6_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Luft BJ, Remington JS: <strong class="EmphasisTypeBold">Toxoplasmic encephalitis in AIDS.</strong>
                  <em class="EmphasisTypeItalic">Clin Infect Dis</em> 1992, <strong class="EmphasisTypeBold">15:</strong>211–222.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1520757"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Toxoplasmic%20encephalitis%20in%20AIDS&amp;author=BJ.%20Luft&amp;author=JS.%20Remington&amp;journal=Clin%20Infect%20Dis&amp;volume=15&amp;pages=211-222&amp;publication_year=1992"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR7_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Jacobs L: <span class="EmphasisTypeBoldItalic">Toxoplasma gondii:</span>
                  <strong class="EmphasisTypeBold">parasitology and transmission.</strong>
                  <em class="EmphasisTypeItalic">Bull N Y Acad Med</em> 1974, <strong class="EmphasisTypeBold">50:</strong>128–145.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=4592094"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Toxoplasma%20gondii%3A%20parasitology%20and%20transmission&amp;author=L.%20Jacobs&amp;journal=Bull%20N%20Y%20Acad%20Med&amp;volume=50&amp;pages=128-145&amp;publication_year=1974"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR8_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Dubey JP: <strong class="EmphasisTypeBold">The History and Life Cycle of</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">.</strong> In <em class="EmphasisTypeItalic">Toxoplasma gondii: The Model Apicomplexan: Perspectives and Methods</em>. Edited by: Weiss LM, Kim K. London: Academic Press; 2007:1–17.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/B978-012369542-0/50003-9"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=The%20History%20and%20Life%20Cycle%20of%20Toxoplasma%20gondii%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20&amp;author=JP.%20Dubey&amp;pages=1-17&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR9_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Boyer K, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, Karrison T, McLeod R: <strong class="EmphasisTypeBold">Risk factors for</strong>
                  <span class="EmphasisTypeBoldItalic">Toxplasma gondii</span>
                  <strong class="EmphasisTypeBold">infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening.</strong>
                  <em class="EmphasisTypeItalic">AJOG</em> 2005, <strong class="EmphasisTypeBold">192:</strong>564–71.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/j.ajog.2004.07.031"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Risk%20factors%20for%20Toxplasma%20gondii%20infection%20in%20mothers%20of%20infants%20with%20congenital%20toxoplasmosis%3A%20implications%20for%20prenatal%20management%20and%20screening&amp;author=K.%20Boyer&amp;author=E.%20Holfels&amp;author=N.%20Roizen&amp;author=C.%20Swisher&amp;author=D.%20Mack&amp;author=J.%20Remington&amp;author=S.%20Withers&amp;author=P.%20Meier&amp;author=T.%20Karrison&amp;author=R.%20McLeod&amp;journal=AJOG&amp;volume=192&amp;pages=564-71&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR10_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">McLeod R, Frenkel JK, Estes RG, Mack DG, Eisenhauer P, Gibori G: <strong class="EmphasisTypeBold">Subcutaneous and intestinal vaccination with tachyzoites of</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">and acquisition of immunity to peroral and congenital</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma</span>
                  <strong class="EmphasisTypeBold">challenge.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 1988, <strong class="EmphasisTypeBold">140:</strong>1632–7.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=3346545"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Subcutaneous%20and%20intestinal%20vaccination%20with%20tachyzoites%20of%20Toxoplasma%20gondii%20and%20acquisition%20of%20immunity%20to%20peroral%20and%20congenital%20Toxoplasma%20challenge&amp;author=R.%20McLeod&amp;author=JK.%20Frenkel&amp;author=RG.%20Estes&amp;author=DG.%20Mack&amp;author=P.%20Eisenhauer&amp;author=G.%20Gibori&amp;journal=J%20Immunol&amp;volume=140&amp;pages=1632-7&amp;publication_year=1988"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR11_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Buxton D, Thomson K, Maley S, Wright S, Bos HJ: <strong class="EmphasisTypeBold">Vaccination of sheep with a live incomplete strain (S48) of</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">and their immunity to challenge when pregnant.</strong>
                  <em class="EmphasisTypeItalic">Vet Rec</em> 1991, <strong class="EmphasisTypeBold">129:</strong>89–93.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1136/vr.129.5.89"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1926725"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Vaccination%20of%20sheep%20with%20a%20live%20incomplete%20strain%20%28S48%29%20of%20Toxoplasma%20gondii%20and%20their%20immunity%20to%20challenge%20when%20pregnant&amp;author=D.%20Buxton&amp;author=K.%20Thomson&amp;author=S.%20Maley&amp;author=S.%20Wright&amp;author=HJ.%20Bos&amp;journal=Vet%20Rec&amp;volume=129&amp;pages=89-93&amp;publication_year=1991"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR12_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Lu F, Huang S, Kasper LH: <strong class="EmphasisTypeBold">The temperature-sensitive mutants of</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">and ocular toxoplasmosis.</strong>
                  <em class="EmphasisTypeItalic">Vaccine</em> 2009, <strong class="EmphasisTypeBold">27:</strong>573–580.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/j.vaccine.2008.10.090"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19026704"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=The%20temperature-sensitive%20mutants%20of%20Toxoplasma%20gondii%20and%20ocular%20toxoplasmosis&amp;author=F.%20Lu&amp;author=S.%20Huang&amp;author=LH.%20Kasper&amp;journal=Vaccine&amp;volume=27&amp;pages=573-580&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR13_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Mévélec MN, Ducournau C, Bassuny Ismael A, Olivier M, Sèche E, Lebrun M, Bout D, Dimier-Poisson I: <strong class="EmphasisTypeBold">Mic1–3 Knockout</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">is a good candidate for a vaccine against</strong>
                  <span class="EmphasisTypeBoldItalic">T. gondii</span>
                  <strong class="EmphasisTypeBold">-induced abortion in sheep.</strong>
                  <em class="EmphasisTypeItalic">Vet Res</em> 2010, <strong class="EmphasisTypeBold">41:</strong>49.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1051/vetres/2010021"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20385082"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Mic1-3%20Knockout%20Toxoplasma%20gondii%20is%20a%20good%20candidate%20for%20a%20vaccine%20against%20T.%20gondii-induced%20abortion%20in%20sheep&amp;author=MN.%20M%C3%A9v%C3%A9lec&amp;author=C.%20Ducournau&amp;author=A.%20Bassuny%20Ismael&amp;author=M.%20Olivier&amp;author=E.%20S%C3%A8che&amp;author=M.%20Lebrun&amp;author=D.%20Bout&amp;author=I.%20Dimier-Poisson&amp;journal=Vet%20Res&amp;volume=41&amp;pages=49&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR14_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Gigley JP, Fox BA, Bzik DJ: <strong class="EmphasisTypeBold">Cell-mediated immunity to</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">develops primarily by local Th-1 host immune responses in the absence of parasite replication.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 2009, <strong class="EmphasisTypeBold">182:</strong>1069–1078.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19124750"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Cell-mediated%20immunity%20to%20Toxoplasma%20gondii%20develops%20primarily%20by%20local%20Th-1%20host%20immune%20responses%20in%20the%20absence%20of%20parasite%20replication&amp;author=JP.%20Gigley&amp;author=BA.%20Fox&amp;author=DJ.%20Bzik&amp;journal=J%20Immunol&amp;volume=182&amp;pages=1069-1078&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR15_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Hutson SL, Mui E, Kinsley K, Witola WH, Behnke MS, El Bissati K, Muench SP, Rohrman B, Liu SR, Wollmann R, Ogata Y, Sarkeshik S, Yates JR III, McLeod R: <span class="EmphasisTypeBoldItalic">T. gondii</span>
                  <strong class="EmphasisTypeBold">RP Promoters &amp; Knockdown Reveal Molecular Pathways Associated with Proliferation and Cell-Cycle Arrest.</strong>
                  <em class="EmphasisTypeItalic">PLoS ONE</em> 2010,<strong class="EmphasisTypeBold">5</strong>(11)<strong class="EmphasisTypeBold">:</strong>e14057.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1371/journal.pone.0014057"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21124925"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=T.%20gondii%20RP%20Promoters%20%26%20Knockdown%20Reveal%20Molecular%20Pathways%20Associated%20with%20Proliferation%20and%20Cell-Cycle%20Arrest&amp;author=SL.%20Hutson&amp;author=E.%20Mui&amp;author=K.%20Kinsley&amp;author=WH.%20Witola&amp;author=MS.%20Behnke&amp;author=K.%20El%20Bissati&amp;author=SP.%20Muench&amp;author=B.%20Rohrman&amp;author=SR.%20Liu&amp;author=R.%20Wollmann&amp;author=Y.%20Ogata&amp;author=S.%20Sarkeshik&amp;author=JR.%20Yates&amp;author=R.%20McLeod&amp;journal=PLoS%20ONE&amp;volume=5&amp;issue=11&amp;pages=e14057&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR16_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Blanchard N, Gonzalez F, Schaeffer M, Joncker NT, Cheng T, Shastri AJ, Robey EA, Shastri N: <strong class="EmphasisTypeBold">Immunodominant, protective response to the parasite</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">requires antigen processing in the endoplasmic reticulum.</strong>
                  <em class="EmphasisTypeItalic">Nat Immunol</em> 2008, <strong class="EmphasisTypeBold">9:</strong>937–944.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1038/ni.1629"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18587399"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Immunodominant%2C%20protective%20response%20to%20the%20parasite%20Toxoplasma%20gondii%20requires%20antigen%20processing%20in%20the%20endoplasmic%20reticulum&amp;author=N.%20Blanchard&amp;author=F.%20Gonzalez&amp;author=M.%20Schaeffer&amp;author=NT.%20Joncker&amp;author=T.%20Cheng&amp;author=AJ.%20Shastri&amp;author=EA.%20Robey&amp;author=N.%20Shastri&amp;journal=Nat%20Immunol&amp;volume=9&amp;pages=937-944&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR17_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Bui HH, Sidney J, Li W, Fusseder N, Sette A: <strong class="EmphasisTypeBold">Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines.</strong>
                  <em class="EmphasisTypeItalic">BMC Bioinformatics</em> 2007, <strong class="EmphasisTypeBold">8:</strong>361.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1186/1471-2105-8-361"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17897458"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Development%20of%20an%20epitope%20conservancy%20analysis%20tool%20to%20facilitate%20the%20design%20of%20epitope-based%20diagnostics%20and%20vaccines&amp;author=HH.%20Bui&amp;author=J.%20Sidney&amp;author=W.%20Li&amp;author=N.%20Fusseder&amp;author=A.%20Sette&amp;journal=BMC%20Bioinformatics&amp;volume=8&amp;pages=361&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR18_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Tan TG, Mui E, Cong H, Witola WH, Montpetit A, Muench SP, Sidney J, Alexander J, Sette A, Grigg M, Maewal A, McLeod R: <strong class="EmphasisTypeBold">Identification of</strong>
                  <span class="EmphasisTypeBoldItalic">T. gondii</span>
                  <strong class="EmphasisTypeBold">epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.</strong>
                  <em class="EmphasisTypeItalic">Vaccine</em> 2010, <strong class="EmphasisTypeBold">28:</strong>3977–3989.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/j.vaccine.2010.03.028"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20347630"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20T.%20gondii%20epitopes%2C%20adjuvants%2C%20and%20host%20genetic%20factors%20that%20influence%20protection%20of%20mice%20and%20humans&amp;author=TG.%20Tan&amp;author=E.%20Mui&amp;author=H.%20Cong&amp;author=WH.%20Witola&amp;author=A.%20Montpetit&amp;author=SP.%20Muench&amp;author=J.%20Sidney&amp;author=J.%20Alexander&amp;author=A.%20Sette&amp;author=M.%20Grigg&amp;author=A.%20Maewal&amp;author=R.%20McLeod&amp;journal=Vaccine&amp;volume=28&amp;pages=3977-3989&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR19_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A: <strong class="EmphasisTypeBold">Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.</strong>
                  <em class="EmphasisTypeItalic">Eur J Immunol</em> 1989, <strong class="EmphasisTypeBold">19:</strong>2237–2242.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1002/eji.1830191209"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2481588"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Universally%20immunogenic%20T%20cell%20epitopes%3A%20promiscuous%20binding%20to%20human%20MHC%20class%20II%20and%20promiscuous%20recognition%20by%20T%20cells&amp;author=P.%20Panina-Bordignon&amp;author=A.%20Tan&amp;author=A.%20Termijtelen&amp;author=S.%20Demotz&amp;author=G.%20Corradin&amp;author=A.%20Lanzavecchia&amp;journal=Eur%20J%20Immunol&amp;volume=19&amp;pages=2237-2242&amp;publication_year=1989"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR20_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Chen YZ, Liu G, Senju S, Wang Q, Irie A, Haruta M, Matsui M, Yasui F, Kohara M, Nishimura Y: <strong class="EmphasisTypeBold">Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.</strong>
                  <em class="EmphasisTypeItalic">Int J Immunopathol Pharmacol</em> 2010, <strong class="EmphasisTypeBold">23:</strong>165–177.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20378004"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20SARS-COV%20spike%20protein-derived%20and%20HLA-A2-restricted%20human%20CTL%20epitopes%20by%20using%20a%20new%20muramyl%20dipeptidederivative%20adjuvant&amp;author=YZ.%20Chen&amp;author=G.%20Liu&amp;author=S.%20Senju&amp;author=Q.%20Wang&amp;author=A.%20Irie&amp;author=M.%20Haruta&amp;author=M.%20Matsui&amp;author=F.%20Yasui&amp;author=M.%20Kohara&amp;author=Y.%20Nishimura&amp;journal=Int%20J%20Immunopathol%20Pharmacol&amp;volume=23&amp;pages=165-177&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR21_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG: <strong class="EmphasisTypeBold">A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis.</strong>
                  <em class="EmphasisTypeItalic">Sci Transl Med</em> 2010, <strong class="EmphasisTypeBold">2:</strong>53ra74.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20944089"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=A%20Defined%20Tuberculosis%20Vaccine%20Candidate%20Boosts%20BCG%20and%20Protects%20Against%20Multidrug-Resistant%20Mycobacterium%20tuberculosis&amp;author=S.%20Bertholet&amp;author=GC.%20Ireton&amp;author=DJ.%20Ordway&amp;author=HP.%20Windish&amp;author=SO.%20Pine&amp;author=M.%20Kahn&amp;author=T.%20Phan&amp;author=IM.%20Orme&amp;author=TS.%20Vedvick&amp;author=SL.%20Baldwin&amp;author=RN.%20Coler&amp;author=SG.%20Reed&amp;journal=Sci%20Transl%20Med&amp;volume=2&amp;pages=53ra74&amp;publication_year=2010"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR22_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">O'Hagan DT, Tsai T, Reed S: <strong class="EmphasisTypeBold">Emulsion-Based Adjuvants for Improved Influenza Vaccines.</strong>
                  <em class="EmphasisTypeItalic">Influenza Vaccines for the Future</em> 2011, in press.</span><span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Emulsion-Based%20Adjuvants%20for%20Improved%20Influenza%20Vaccines&amp;author=DT.%20O%27Hagan&amp;author=T.%20Tsai&amp;author=S.%20Reed&amp;publication_year=2011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR23_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Reed SG, Bertholet S, Coler RN, Friede M: <strong class="EmphasisTypeBold">New horizons in adjuvants for vaccine development.</strong>
                  <em class="EmphasisTypeItalic">Trends Immunol</em> 2009, <strong class="EmphasisTypeBold">30:</strong>S23–32.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/j.it.2008.09.006"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=New%20horizons%20in%20adjuvants%20for%20vaccine%20development&amp;author=SG.%20Reed&amp;author=S.%20Bertholet&amp;author=RN.%20Coler&amp;author=M.%20Friede&amp;journal=Trends%20Immunol&amp;volume=30&amp;pages=S23-32&amp;publication_year=2009"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR24_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG: <strong class="EmphasisTypeBold">Taking toll: lipid A mimetics as adjuvants and immunomodulators.</strong>
                  <em class="EmphasisTypeItalic">Trends Microbiol</em> 2002, <strong class="EmphasisTypeBold">10:</strong>S32–37.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/S0966-842X(02)02426-5"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12377566"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Taking%20toll%3A%20lipid%20A%20mimetics%20as%20adjuvants%20and%20immunomodulators&amp;author=DH.%20Persing&amp;author=RN.%20Coler&amp;author=MJ.%20Lacy&amp;author=DA.%20Johnson&amp;author=JR.%20Baldridge&amp;author=RM.%20Hershberg&amp;author=SG.%20Reed&amp;journal=Trends%20Microbiol&amp;volume=10&amp;pages=S32-37&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR25_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, Sakabetis E, Brown LE: <strong class="EmphasisTypeBold">Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.</strong>
                  <em class="EmphasisTypeItalic">J Virol</em> 2002, <strong class="EmphasisTypeBold">76:</strong>4212–4221.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1128/JVI.76.9.4212-4221.2002"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11932386"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Induction%20of%20long-term%20memory%20CD8%28%2B%29%20T%20cells%20for%20recall%20of%20viral%20clearing%20responses%20against%20influenza%20virus&amp;author=G.%20Deliyannis&amp;author=DC.%20Jackson&amp;author=NJ.%20Ede&amp;author=W.%20Zeng&amp;author=I.%20Hourdakis&amp;author=E.%20Sakabetis&amp;author=LE.%20Brown&amp;journal=J%20Virol&amp;volume=76&amp;pages=4212-4221&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR26_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">BenMohamed L, Wechsler SL, Nesburn AB: <strong class="EmphasisTypeBold">: Lipopeptide vaccines--yesterday, today, and tomorrow.</strong>
                  <em class="EmphasisTypeItalic">Lancet Infect Dis</em> 2002, <strong class="EmphasisTypeBold">2:</strong>425–431.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/S1473-3099(02)00318-3"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12127354"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=%3A%20Lipopeptide%20vaccines--yesterday%2C%20today%2C%20and%20tomorrow&amp;author=L.%20BenMohamed&amp;author=SL.%20Wechsler&amp;author=AB.%20Nesburn&amp;journal=Lancet%20Infect%20Dis&amp;volume=2&amp;pages=425-431&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR27_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC: <strong class="EmphasisTypeBold">Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 2002, <strong class="EmphasisTypeBold">169:</strong>4905–4912.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12391202"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Highly%20immunogenic%20and%20totally%20synthetic%20lipopeptides%20as%20self-adjuvanting%20immunocontraceptive%20vaccines&amp;author=W.%20Zeng&amp;author=S.%20Ghosh&amp;author=YF.%20Lau&amp;author=LE.%20Brown&amp;author=DC.%20Jackson&amp;journal=J%20Immunol&amp;volume=169&amp;pages=4905-4912&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR28_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Chua BY, Zeng W, Jackson DC: <strong class="EmphasisTypeBold">Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.</strong>
                  <em class="EmphasisTypeItalic">Methods Mol Biol</em> 2008, <strong class="EmphasisTypeBold">494:</strong>247–261.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1007/978-1-59745-419-3_14"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18726578"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Synthesis%20of%20toll-like%20receptor-2%20targeting%20lipopeptides%20as%20self-adjuvanting%20vaccines&amp;author=BY.%20Chua&amp;author=W.%20Zeng&amp;author=DC.%20Jackson&amp;journal=Methods%20Mol%20Biol&amp;volume=494&amp;pages=247-261&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR29_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Tsunoda I, Sette A, Fujinami RS, Oseroff C, Ruppert J, Dahlberg C, Southwood S, Arrhenius T, Kuang LQ, Kubo RT, Chesnut RW, Ishioka GY: <strong class="EmphasisTypeBold">Lipopeptide particles as the immunologically active component of CTL inducing vaccines.</strong>
                  <em class="EmphasisTypeItalic">Vaccine</em> 1999, <strong class="EmphasisTypeBold">17:</strong>675–685.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/S0264-410X(98)00250-3"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10067673"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Lipopeptide%20particles%20as%20the%20immunologically%20active%20component%20of%20CTL%20inducing%20vaccines&amp;author=I.%20Tsunoda&amp;author=A.%20Sette&amp;author=RS.%20Fujinami&amp;author=C.%20Oseroff&amp;author=J.%20Ruppert&amp;author=C.%20Dahlberg&amp;author=S.%20Southwood&amp;author=T.%20Arrhenius&amp;author=LQ.%20Kuang&amp;author=RT.%20Kubo&amp;author=RW.%20Chesnut&amp;author=GY.%20Ishioka&amp;journal=Vaccine&amp;volume=17&amp;pages=675-685&amp;publication_year=1999"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR30_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Brown CR, McLeod R: <strong class="EmphasisTypeBold">Class I MHC genes and CD8+ T cells determine cyst number in</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">infection.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 1990, <strong class="EmphasisTypeBold">145:</strong>3438–3441.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=2121825"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Class%20I%20MHC%20genes%20and%20CD8%2B%20T%20cells%20determine%20cyst%20number%20in%20Toxoplasma%20gondii%20infection&amp;author=CR.%20Brown&amp;author=R.%20McLeod&amp;journal=J%20Immunol&amp;volume=145&amp;pages=3438-3441&amp;publication_year=1990"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR31_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A: <strong class="EmphasisTypeBold">Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">vaccine.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 1991, <strong class="EmphasisTypeBold">146:</strong>286–292.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1670604"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Synergistic%20role%20of%20CD4%2B%20and%20CD8%2B%20T%20lymphocytes%20in%20IFN-gamma%20production%20and%20protective%20immunity%20induced%20by%20an%20attenuated%20Toxoplasma%20gondii%20vaccine&amp;author=RT.%20Gazzinelli&amp;author=FT.%20Hakim&amp;author=S.%20Hieny&amp;author=GM.%20Shearer&amp;author=A.%20Sher&amp;journal=J%20Immunol&amp;volume=146&amp;pages=286-292&amp;publication_year=1991"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR32_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A: <strong class="EmphasisTypeBold">Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 1992, <strong class="EmphasisTypeBold">149:</strong>175–180.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=1351500"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Simultaneous%20depletion%20of%20CD4%2B%20and%20CD8%2B%20T%20lymphocytes%20is%20required%20to%20reactivate%20chronic%20infection%20with%20Toxoplasma%20gondii%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20&amp;author=R.%20Gazzinelli&amp;author=Y.%20Xu&amp;author=S.%20Hieny&amp;author=A.%20Cheever&amp;author=A.%20Sher&amp;journal=J%20Immunol&amp;volume=149&amp;pages=175-180&amp;publication_year=1992"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR33_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A: <strong class="EmphasisTypeBold">Alterred helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 1999, <strong class="EmphasisTypeBold">162:</strong>3088–3095.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10072562"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Alterred%20helper%20T%20lymphocyte%20function%20associated%20with%20chronic%20hepatitis%20B%20virus%20infection%20and%20its%20role%20in%20response%20to%20therapeutic%20vaccination%20in%20humans&amp;author=BD.%20Livingston&amp;author=J.%20Alexander&amp;author=C.%20Crimi&amp;author=C.%20Oseroff&amp;author=E.%20Celis&amp;author=K.%20Daly&amp;author=LG.%20Guidotti&amp;author=FV.%20Chisari&amp;author=J.%20Fikes&amp;author=RW.%20Chesnut&amp;author=A.%20Sette&amp;journal=J%20Immunol&amp;volume=162&amp;pages=3088-3095&amp;publication_year=1999"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR34_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari FV, Guidotti LG, Chesnut RW, Livingston B, Sette A: <strong class="EmphasisTypeBold">The optimization of helper T lymphocyte (HTL) function in vaccine development.</strong>
                  <em class="EmphasisTypeItalic">Immunol Res</em> 1998, <strong class="EmphasisTypeBold">18:</strong>79–92.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1007/BF02788751"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9844827"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=The%20optimization%20of%20helper%20T%20lymphocyte%20%28HTL%29%20function%20in%20vaccine%20development&amp;author=J.%20Alexander&amp;author=J.%20Fikes&amp;author=S.%20Hoffman&amp;author=E.%20Franke&amp;author=J.%20Sacci&amp;author=E.%20Appella&amp;author=FV.%20Chisari&amp;author=LG.%20Guidotti&amp;author=RW.%20Chesnut&amp;author=B.%20Livingston&amp;author=A.%20Sette&amp;journal=Immunol%20Res&amp;volume=18&amp;pages=79-92&amp;publication_year=1998"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR35_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, Fikes J, Newman M, Chesnut RW, Morton PA, Fok K, Appella E, Sette A: <strong class="EmphasisTypeBold">A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 2002, <strong class="EmphasisTypeBold">168:</strong>6189–6198.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12055232"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=A%20decaepitope%20polypeptide%20primes%20for%20multiple%20CD8%2B%20IFN-gamma%20and%20Th%20lymphocyte%20responses%3A%20evaluation%20of%20multiepitope%20polypeptides%20as%20a%20mode%20for%20vaccine%20delivery&amp;author=J.%20Alexander&amp;author=C.%20Oseroff&amp;author=C.%20Dahlberg&amp;author=M.%20Qin&amp;author=G.%20Ishioka&amp;author=M.%20Beebe&amp;author=J.%20Fikes&amp;author=M.%20Newman&amp;author=RW.%20Chesnut&amp;author=PA.%20Morton&amp;author=K.%20Fok&amp;author=E.%20Appella&amp;author=A.%20Sette&amp;journal=J%20Immunol&amp;volume=168&amp;pages=6189-6198&amp;publication_year=2002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR36_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Debierre-Grockiego F, Campos MA, Azzouz N, Schmidt J, Bieker U, Resende MG, Mansur DS, Weingart R, Schmidt RR, Golenbock DT, Gazzinelli RT, Schwarz RT: <strong class="EmphasisTypeBold">Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">.</strong>
                  <em class="EmphasisTypeItalic">J Immunol</em> 2007, <strong class="EmphasisTypeBold">179:</strong>1129–1137.</span><span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17617606"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Activation%20of%20TLR2%20and%20TLR4%20by%20glycosylphosphatidylinositols%20derived%20from%20Toxoplasma%20gondii%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20&amp;author=F.%20Debierre-Grockiego&amp;author=MA.%20Campos&amp;author=N.%20Azzouz&amp;author=J.%20Schmidt&amp;author=U.%20Bieker&amp;author=MG.%20Resende&amp;author=DS.%20Mansur&amp;author=R.%20Weingart&amp;author=RR.%20Schmidt&amp;author=DT.%20Golenbock&amp;author=RT.%20Gazzinelli&amp;author=RT.%20Schwarz&amp;journal=J%20Immunol&amp;volume=179&amp;pages=1129-1137&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR37_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Kim SK, Karasov A, Boothroyd JC: <strong class="EmphasisTypeBold">Bradyzoite-specific surface antigen SRS9 plays a role in maintaining</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">persistence in the brain and in host control of parasite replication in the intestine.</strong>
                  <em class="EmphasisTypeItalic">Infect Immun</em> 2007, <strong class="EmphasisTypeBold">75:</strong>1626–1634.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1128/IAI.01862-06"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17261600"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Bradyzoite-specific%20surface%20antigen%20SRS9%20plays%20a%20role%20in%20maintaining%20Toxoplasma%20gondii%20persistence%20in%20the%20brain%20and%20in%20host%20control%20of%20parasite%20replication%20in%20the%20intestine&amp;author=SK.%20Kim&amp;author=A.%20Karasov&amp;author=JC.%20Boothroyd&amp;journal=Infect%20Immun&amp;volume=75&amp;pages=1626-1634&amp;publication_year=2007"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR38_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Saeij JP, Arrizabalaga G, Boothroyd JC: <strong class="EmphasisTypeBold">A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">persistence.</strong>
                  <em class="EmphasisTypeItalic">Infect Immun</em> 2008, <strong class="EmphasisTypeBold">76:</strong>2402–2410.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1128/IAI.01494-07"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18347037"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=A%20cluster%20of%20four%20surface%20antigen%20genes%20specifically%20expressed%20in%20bradyzoites%2C%20SAG2CDXY%2C%20plays%20an%20important%20role%20in%20Toxoplasma%20gondii%20persistence&amp;author=JP.%20Saeij&amp;author=G.%20Arrizabalaga&amp;author=JC.%20Boothroyd&amp;journal=Infect%20Immun&amp;volume=76&amp;pages=2402-2410&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR39_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC: <strong class="EmphasisTypeBold">Bioluminescence imaging of</strong>
                  <span class="EmphasisTypeBoldItalic">Toxoplasma gondii</span>
                  <strong class="EmphasisTypeBold">infection in living mice reveals dramatic differences between strains.</strong>
                  <em class="EmphasisTypeItalic">Infect Immun</em> 2005, <strong class="EmphasisTypeBold">73:</strong>695–702.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1128/IAI.73.2.695-702.2005"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15664907"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Bioluminescence%20imaging%20of%20Toxoplasma%20gondii%20infection%20in%20living%20mice%20reveals%20dramatic%20differences%20between%20strains&amp;author=JP.%20Saeij&amp;author=JP.%20Boyle&amp;author=ME.%20Grigg&amp;author=G.%20Arrizabalaga&amp;author=JC.%20Boothroyd&amp;journal=Infect%20Immun&amp;volume=73&amp;pages=695-702&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR40_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui HH, Grey H, Sette A: <strong class="EmphasisTypeBold">A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus.</strong>
                  <em class="EmphasisTypeItalic">Nat Biotechnol</em> 2006, <strong class="EmphasisTypeBold">24:</strong>817–819.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1038/nbt1215"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16767078"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=A%20consensus%20epitope%20prediction%20approach%20identifies%20the%20breadth%20of%20murine%20T%28CD8%2B%29-cell%20responses%20to%20vaccinia%20virus&amp;author=M.%20Moutaftsi&amp;author=B.%20Peters&amp;author=V.%20Pasquetto&amp;author=DC.%20Tscharke&amp;author=J.%20Sidney&amp;author=HH.%20Bui&amp;author=H.%20Grey&amp;author=A.%20Sette&amp;journal=Nat%20Biotechnol&amp;volume=24&amp;pages=817-819&amp;publication_year=2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR41_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Gulukota K, Sidney J, Sette A, DeLisi C: <strong class="EmphasisTypeBold">Two complementary methods for predicting peptides binding major histocompatibility complex molecules.</strong>
                  <em class="EmphasisTypeItalic">J Mol Biol</em> 1997, <strong class="EmphasisTypeBold">267:</strong>1258–1267.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1006/jmbi.1997.0937"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9150410"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Two%20complementary%20methods%20for%20predicting%20peptides%20binding%20major%20histocompatibility%20complex%20molecules&amp;author=K.%20Gulukota&amp;author=J.%20Sidney&amp;author=A.%20Sette&amp;author=C.%20DeLisi&amp;journal=J%20Mol%20Biol&amp;volume=267&amp;pages=1258-1267&amp;publication_year=1997"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR42_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B: <strong class="EmphasisTypeBold">: Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries.</strong>
                  <em class="EmphasisTypeItalic">Immunome Res</em> 2008, <strong class="EmphasisTypeBold">4:</strong>2.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1186/1745-7580-4-2"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18221540"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=%3A%20Quantitative%20peptide%20binding%20motifs%20for%2019%20human%20and%20mouse%20MHC%20class%20I%20molecules%20derived%20using%20positional%20scanning%20combinatorial%20peptide%20libraries&amp;author=J.%20Sidney&amp;author=E.%20Assarsson&amp;author=C.%20Moore&amp;author=S.%20Ngo&amp;author=C.%20Pinilla&amp;author=A.%20Sette&amp;author=B.%20Peters&amp;journal=Immunome%20Res&amp;volume=4&amp;pages=2&amp;publication_year=2008"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR43_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM: <strong class="EmphasisTypeBold">Chapter 18, Measurement of MHC/peptide interactions by gel filtration.</strong>
                  <em class="EmphasisTypeItalic">Curr Protoc Immunol</em> 2001, <strong class="EmphasisTypeBold">Chapter 18:</strong>Unit 18.13.</span><span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Chapter%2018%2C%20Measurement%20of%20MHC%2Fpeptide%20interactions%20by%20gel%20filtration&amp;author=J.%20Sidney&amp;author=S.%20Southwood&amp;author=C.%20Oseroff&amp;author=MF.%20del%20Guercio&amp;author=A.%20Sette&amp;author=HM.%20Grey&amp;journal=Curr%20Protoc%20Immunol&amp;volume=Chapter%2018&amp;pages=Unit%2018.13&amp;publication_year=2001"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR44_50" itemprop="citation" itemscope="" itemtype="http://schema.org/ScholarlyArticle"><span itemprop="headline">Cheng Y, Prusoff WH: <strong class="EmphasisTypeBold">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.</strong>
                  <em class="EmphasisTypeItalic">Biochem Pharmacol</em> 1973, <strong class="EmphasisTypeBold">22:</strong>3099–3108.</span><span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" rel="noopener" href="https://doi.org/10.1016/0006-2952(73)90196-2"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" rel="noopener nofollow" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=4202581"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" rel="noopener" href="http://scholar.google.com/scholar_lookup?title=Relationship%20between%20the%20inhibition%20constant%20%28K1%29%20and%20the%20concentration%20of%20inhibitor%20which%20causes%2050%20per%20cent%20inhibition%20%28I50%29%20of%20an%20enzymatic%20reaction&amp;author=Y.%20Cheng&amp;author=WH.%20Prusoff&amp;journal=Biochem%20Pharmacol&amp;volume=22&amp;pages=3099-3108&amp;publication_year=1973"><span><span>Google Scholar</span></span></a></span></span></cite></li></ol></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 c-section" id="CopyrightMessage"><h2 class="Heading js-ToggleCollapseSection c-section__heading" data-sticky-update="true"><a href="#Congetal" data-toggle="collapse" data-toggle-disable-clickoff="" data-target="Congetal">Copyright</a></h2><div class="js-CollapseSection CollapseSection c-section__content" data-test="collapse-section" id="Congetal"><div xmlns="http://www.w3.org/1999/xhtml" class="ArticleCopyright">©&nbsp;Cong et al.&nbsp;2010<div class="CopyrightComment">
                                <p xmlns="" class="SimplePara">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/licenses/by/2.0" target="_blank" class="ext-link"><span class="RefSource">http://creativecommons.org/licenses/by/2.0</span></a></span>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
                            </div></div></div></section></div>



                        </article>
                    </main>
                </div>
            </div>
        </div>
    </div>
</section>
